Factors Governing Photodynamic Cross-Linking of Ocular Coat by Huynh, Joyce
 Factors Governing Photodynamic  
Cross-linking of Ocular Coat 
 
Thesis by 
Joyce Huynh 
 
In Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
 
 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
2011 
(Defended May 6, 2011) 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2011 
Joyce Huynh 
All Rights Reserved 
 
iii 
 
 
 
 
Dedicated to Mom and Dad 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGMENTS 
First, I would like to express my deepest gratitude to my thesis advisor, Prof. Julie 
Kornfield who is always understanding, supportive, and encouraging. I thank her for the 
guidance throughout my thesis project. She has provided me with advice when I needed it 
and at the same time granted me the freedom to explore my creativity. Julie’s enthusiasm 
for science, passion for learning, and dedication to teaching have inspired me greatly 
throughout my graduate school experience. 
I am grateful to have the opportunity to work with Matthew Mattson. He has been a 
wonderful mentor and friend since the first day I joined the Kornfield Lab. When I first 
joined the group, Matthew taught me everything I needed to know to get started with the 
research project. He continues to play an important role in my research project by 
providing valuable advice and contributions. I feel very fortunate to have had the 
opportunity to work closely with him over the last four years. He is always patient, kind, 
and encouraging when mentoring me. In addition to being an exceptional mentor, he is 
also a wonderful friend.  
I thank our collaborators Dr. Daniel Schwartz and Dr. Keith Duncan at the University of 
California, San Francisco for providing resources and expertise on the clinical aspects of 
the project. I deeply appreciate everyone in the Kornfield group for their support and 
guidance. Group members were always very willing to share their expertise to help me 
accomplish what I needed to do. I would also like to thank the secretaries in the chemical 
engineering department, especially Ms. Anne Hormann, Ms. Marcy Fowler, and Ms. 
Kathy Bubash for handling all the logistics.  
vi 
 
I am very glad to have the opportunity to work with undergraduate students: Viet Anh 
Nguyen Huu, Joyce Liu, and Alex Wang. Viet Anh is the first undergraduate student I 
worked with and it has been a remarkable experience mentoring him over the last three 
years. He is always very excited about the research and experiments which makes 
working with him an enjoyable and rewarding experience. Joyce and Alex are also very 
diligent students who have made valuable contributions to the research project as well.  
I thank all my chemical engineering classmates who made going through first year 
manageable and fun. They continued to be an important source of support throughout the 
program. I also thank all my friends at Caltech for making my time here very memorable.  
I would like to send very special thanks to my friends outside of Caltech as well. Diana, I 
am glad you were at UCLA making each weekend we hung out filled with fun activities 
and unforgettable memories. Gina, ever since you came back to LA, it has been an on-
going party. Cindy, even though we have not lived in the same city since high school, it is 
wonderful to know you are always there for me. Eileen, I am grateful for all the laughter 
we share.     
Finally, I am extremely grateful for my family. Most of all I would like to thank my mom 
and dad for their unconditional love and support. For as long as I can remember, they 
have always taught me to value education and knowledge. Growing up I listened to their 
teaching with faith and as I grew older I began to understand. Now more than ever 
before, I truly appreciate the value of education. I am very grateful for my sister, 
Candice, who is always interesting to talk to about anything and everything. She is filled 
vii 
 
with intriguing ideas and theories that challenge me to think and provide me with 
profound insights. I thank my brother, sister-in-law, and nieces for their love and support.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
ABSTRACT 
This thesis addresses the challenge of minimizing toxicity of therapeutic protein-protein 
cross-linking of the cornea and sclera.  Protein-protein cross-links include disulfide 
bonds, enzymatic cross-links and non-enzymatic cross-links. Disulfide bonds and 
enzymatic cross-links are closely regulated in the body. Non-enzymatic cross-links 
accumulate in an uncontrolled manner, often leading to deleterious effects. Clinically, 
non-enzymatic cross-links can be inserted in a controlled manner, both temporally and 
spatially, using photo-activation to achieve effects ranging from killing tumors to 
stabilizing ocular shape.   
The shape of the eye is maintained by the ocular coat—the cornea and sclera. Diseases 
that result in progressive shape changes can lead to blindness (degenerative myopia) or 
necessitate a corneal transplant (keratoconus and post-LASIK ectasia). Photodynamic 
corneal cross-linking, pioneered by Wollensak et al. using riboflavin activated by near-
ultraviolet  light (riboflavin/UVA), halts the progression of keratoconus; if applied to the 
sclera, it might halt the progression of degenerative myopia, as well. However, this 
treatment suffers from severe cytotoxicity. The literature to date implicitly assumes that 
photodynamic cross-linking is inherently toxic. The present research demonstrates that 
protein-protein cross-linking can be achieved with minimal toxicity using eosin Y 
activated by visible light (eosin Y/visible). 
At a molecular level, both eosin Y/visible and riboflavin/UVA are shown to act through a 
singlet oxygen mechanism; therefore, they are expected to produce similar covalent 
modifications of collagenous tissues. Real-time measurements of the increase in elastic 
ix 
 
modulus during irradiation show that the eosin Y/visible and riboflavin/UVA produce 
similar rates of cross-linking. The transport coefficients of both eosin Y and riboflavin 
were measured for both sclera and de-epithelialized cornea. The diffusivity and partition 
coefficient values, together with the cross-linking kinetics, were used in a predictive 
model of the cross-linking profile as a function of treatment parameters. The predictive 
model also serves as an optimization tool for guiding the selection of treatment 
parameters in pre-clinical studies. In contrast to the dramatic toxicity of the 
riboflavin/UVA treatment (which kills all of the keratocytes and the endothelium in the 
rabbit model), the eosin Y/visible treatment achieves comparable cross-linking with 
negligible phototoxicity. 
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Chapter 1 
Introduction 
 
1.1 PROTEIN-PROTEIN CROSS-LINKS 
Protein-protein cross-links are ubiquitous in biological systems. The most familiar are 
disulfide bonds, which form both intramolecularly and/or intermolecularly to yield proper 
protein folding and function. Similarly, enzymatic cross-links are inserted to confer 
proper function (e.g., maturation of collagen during development). Enzymatic cross-
linking is regulated to confer precise spatial and temporal control, yielding a cross-
linking density that is appropriate for the tissue function. A third, familiar class of 
protein-protein cross-links are the non-enzymatic cross-links that occur throughout our 
lifetime in a manner that is sensitive to diet and lifestyle (e.g., they are inhibited by 
consuming anti-oxidants and vitamins and are exacerbated by exposure to sunlight). In 
contrast to enzymatic cross-links, non-enzymatic cross-links accumulate in an 
uncontrolled manner. Non-enzymatic cross-links are formed without spatial or temporal 
regulation. Proteins with low turn-over rates accumulate these cross-links, which can 
have deleterious effects (e.g., wrinkles in skin[1, 2], hardening of arteries[3, 4], formation of 
amyloid plaques[5, 6]). Perhaps the least familiar type is “therapeutic cross-linking” in 
which a disease is treated by triggering protein-protein cross-links. Therapeutic cross-
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links are inserted in a controlled manner, both spatially and temporally, to serve purposes 
that range from killing tumors to stabilizing the shape of the eye.  
1.2 PHOTODYNAMIC THERAPY 
Clinically, spatial and temporal control is achieved with photo-activated cross-linkers that 
remain inactive until they are irradiated. Using photo-activated molecules decouples the 
reaction and diffusion processes, allowing diffusion to penetrate the desired tissue while 
the drug is inactive. By irradiating only at desired locations, cross-linking can be 
achieved selectively in the intended tissues; inactive molecules present in other tissues 
simply diffuse away with time.  
In contrast to treatments that rely on phototoxicity, such as photodynamic therapy for 
cancer or macular degeneration, other applications of photodynamic cross-linking aim to 
strengthen diseased tissue with minimal toxicity. Two important examples are 
strengthening the sclera to halt the progression of degenerative myopia, and strengthening 
the cornea to halt the progression of keratoconus and other corneal ectasias. The present 
thesis focuses on photodynamic cross-linking therapy for stabilizing the shape of the eye, 
with particular attention to designing treatments that minimize toxicity.   
1.3 DISEASES THAT DESTABILIZE OCULAR SHAPE 
The shape of the eye is maintained by the ocular coat, which consists of the cornea and 
sclera. The sclera is the white part of the eye making up 5/6 of the total surface area of 
the eye. Its function is to provide support and protect the eye. The cornea is the clear 
tissue in front of the eye, which provides ~2/3 of the total focusing power. Diseases 
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associated with changes in the shape of the sclera (e.g. degenerative myopia, Figure 1.1) 
or cornea (e.g. keratoconus and post-LASIK ectasia, Figure 1.1c) lead to loss of visual 
acuity due to distortion of the retina or of the refractive surface that is responsible for 
most of the lens power of the eye, respectively.  
 
  a)  
    
  b)         
   
 c)  
 
Figure 1.1. a) A normal eye. Thinning and stretching in the b) posterior sclera in 
degenerative myopia and c) cornea in keratoconus. (Images adapted from Mattson[7]) 
 
Degenerative myopia is the leading cause of blindness in Asian countries and is ranked 
7th in the United States[8-12]. While there are treatments that can reduce the symptoms 
associated with the disease, there is no treatment that halts the progressive stretching and 
thinning of scleral tissues (Figure 1.1b). Axial elongation due to stretching of the sclera 
causes objects far away to be focused in front of the retinal photoreceptor plane, resulting 
in blurry vision. As the disease progresses, stretching of retinal and choroidal tissues 
damages these tissues resulting in loss of vision. In degenerative myopia, the sclera is 
found to be up to 5% thinner than normal at the posterior pole[13]. The altered structure of 
the sclera is considered to be a significant factor in contributing to the chorio-retinal 
damage. 
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Various efforts have been made to enhance the weakened sclera such as polymerization 
of foam at the posterior pole and scleroplasty but none showed the ability to arrest the 
disease[14, 15]. Scleroplasty is a scleral reinforcement surgery which places a graft at the 
posterior pole to support the weakened structure. Different surgical methods and a variety 
of materials have been tried for scleroplasty but none were successful.  
Keratoconus is a bilateral corneal thinning disorder. This disease has a prevalence of 
1/2000 with no racial or gender bias[16, 17]. This disease is characterized by progressive 
corneal thinning, protrusion, and scarring, resulting in irregular astigmatism and myopia 
(Figure 1.1c). Corneal steepening due to protrusion of the cornea causes the cornea’s 
focusing power to increase; images come to a focus in front of the retina, resulting in 
blurry vision.  
Corneal thinning due to keratoconus results in visual impairment that can initially be 
corrected by spectacles. When eyeglasses are no longer sufficient to provide clear vision, 
contact lenses are used. Surgical procedures, such as thermokeratoplasty[18], 
epikeratophakia[19], and intracornea ring segments[20] have been performed on those who 
are intolerant of contact lenses. These treatments do not halt the progression of 
keratoconus; they only correct refractive errors induced by irregular corneal thinning 
associated with the disease. When the disease progresses to the stage that refractive 
correction is no longer effective, a corneal transplant (keratoplasty) is required. About 
20% of patients with keratoconus ultimately require keratoplasty[16]. 
Similarities between degenerative myopia and keratoconus – Similar to the sclera in 
degenerative myopia, change in the structure of the cornea is a significant factor in 
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contributing to protrusion. Collagen type I is the major structural component of the 
sclera, accounting for 23% of its total mass and 75% of its dry mass[21]. The cornea’s 
chemical composition is very similar to the sclera, with collagen type I being the major 
structural component, contributing 15% of its total mass and 68% of its dry mass[21]. On a 
molecular level, collagen type I consists of three alpha chains spiraling around one 
another to form a triple helix. Individual triple-helical molecules are enzymatically cross-
linked to one another during development to create long parallel collagen fibrils (Figure 
1.2a). In both the sclera and the cornea, collagen fibrils are embedded in a gel-like matrix 
of proteoglycans and water (Figure 1.2b-c). Proteoglycans consist of protein cores with 
glycosaminoglycans attached along their lengths.  
 
  a)  
 
b)          
 
c)  
 
Figure 1.2. Structure of a) a collagen fibril (image adapted from www.nanobiomed.de).  
b) a proteoglycan c) collagen fibrils immersed in a gel-like matrix of water and 
proteoglycans. (Images b and c are adapted from Oyster[22]) 
 
 
The difference in optical properties between the sclera and cornea is due to the 
differences in the size, spacing and orientation of the collagen fibrils. Scleral collagen 
fibrils vary in both diameter (30 to 300 nm) and spacing (250 to 280nm)[23]. They form an 
interweaving morphology conferring great strength to the sclera to protect the eye  
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(Figure 1.3a). The white appearance of the sclera (and the opacity that is vital to its 
function) is due to light scattering from heterogeneities in fibril diameter, fibril spacing 
and fibril orientation on length scales from 150 to 600 nm. In contrast, corneal collagen 
fibrils are very regular in their diameters (20 to 33 nm) and spacing (~60 nm)[23]. The 
highly regular fibril/proteoglycan structures form sheets (“lamellae”) that are stacked 
such that the collagen fibrils lie in the plane of the tissue, giving the cornea its unique 
combination of transparency and strength (Figure 1.3b).  
 
a) 
   
 
b) 
 
Figure 1.3. Fibrils form a) parallel lamellae in the cornea and b) interweaving 
morphology in the sclera. (Images adapted from Komai[24]) 
 
Abnormalities in these structures either in their building block materials or in their 
morphology can result in malfunctioning of the eye. Studies of degenerative myopia and 
keratoconus reveal that similar factors contribute to the thinning process. In degenerative 
myopia, the sclera has a lower content of collagen due to a decrease in production rate of 
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collagen and an increase in degradation rate of collagen[25-29]. There is also a shift in the 
distribution of fibril diameter resulting in smaller fibrils with the greatest reduction 
occurring in the outer layer of the sclera[30]. Similarly, in keratoconus, cornea thinning 
results from loss of material due to an increase in degradation rate of collagen[16, 31-33]. 
This leads to cornea of keratoconus eyes to have fewer collagen lamellae and fewer 
collagen fibrils per lamella[16, 34]. Thus, in both degenerative myopia and keratoconus, 
inadequate tissue strength and over-active collagen turnover result in mechanically 
weakened tissue.  
Based on the similarities in composition of the sclera and cornea, and the similarities in 
the molecular basis of both degenerative myopia and keratoconus, Wollensak and 
Spoerl[35] suggested that it might be possible to develop similar treatments for the two 
diseases. Specifically, they examined the possibility that photodynamic cross-linking 
might be effective in strengthening the sclera and the cornea.    
1.4 CROSS-LINKING TREATMENT 
Based on the hypothesis that additional cross-links in the cornea protect against 
development of keratoconus, Wollensak, Seiler, Spoerl, et al. searched for ways to cross-
link the cornea. Common cross-linkers such as glyceraldehyde and glutaraldehyde do not 
allow for control over when and where the cross-linking occurs. The diffusion process 
and reaction are coupled in these molecules; they diffuse until they are consumed by the 
reaction. Even though the use of glyceraldehyde lacks spatial and temporal control, 
efforts have been invested to develop clinical cross-linking treatments[36, 37]. Using photo-
activated molecules allows for spatial and temporal control over the cross-linking 
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process. Riboflavin, also known as vitamin B2, was selected as the photosensitizer to 
cross-link the cornea since it was recently demonstrated to cross-link vitreous 
collagen[36]. 
In their earliest study in 1997, Wollensak, Seiler, Spoerl, et al. increased the mechanical 
strength of porcine corneas cross-linked with riboflavin and UVA irradiation 365 nm[36]. 
Their subsequent studies examined changes in the thermomechanical[38], hydration[39], 
ultrastructural[40], and biochemical[41, 42] behaviors in treated tissue. The results showed 
that cross-links formed between collagen molecules and are stable with respect to 
reducing agents (mercaptoethanol) chemical, heat, and peptidase (collagenase, pepsin and 
trypsin). They found that the extent of cross-linking induced by riboflavin/UVA varies 
with stromal depth, essentially confined to the anterior 300 μm. 
Promising results with riboflavin/UVA in pre-clinical studies led Wollensak et al. to 
begin treating progressive keratoconus patients in 1998[43] (Figure 1.4). The pilot study in 
Dresden included a total of 22 patients. The treatment protocol involved removing the 
epithelium in the central 7-mm diameter. Next a riboflavin solution (0.1% riboflavin, 
20% dextran) was applied to the cornea 5 minutes before, and then every 5 minutes 
during a 30-minute UVA irradiation (3 mW/cm2 at 370 nm). Patient follow-up ranged 
from 3 months to 4 years. The treatment halted the progression of the disease in all eyes 
and in 70% of the eyes, regression occurred. After re-epithelialization and repopulation of 
keratocytes, there were no adverse effects on corneal transparency and endothelial cell 
density. This treatment is currently being used in Europe and going through FDA clinical 
trials in the United States. 
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  a)  
  
  b)         
        
 c)  
   
 d) 
 
Figure 1.4. a) Riboflavin as a photosensitizer for inducing cross-links. b) Treatment 
involves removing the epithelial cell layer, b) applying drops of riboflavin solution onto 
the cornea, c) irradiating the cornea. (Images c & d adapted from Mattson[7]) 
 
Since the cornea and sclera consist of the same building blocks, it is hypothesized that 
treatments that can strengthen the cornea might also strengthen the sclera. Therefore, 
investigators have also tested riboflavin/UVA cross-linking treatment in rabbit sclera in 
order to treat degenerative myopia[44]. Cross-linking treatment increased scleral strength 
as hypothesized. 
Riboflavin/UVA cross-linking treatment halts the progression of keratoconus and can 
potentially be used treat degenerative myopia. This treatment is novel and is the first 
clinical procedure to address keratoconus directly, instead of only correcting refractive 
errors resulting from the disease.  
1.5 CORNEAL CROSS-LINKING WITH MINIMAL TOXICITY  
Even though riboflavin/UVA corneal cross-linking has demonstrated the ability to halt 
the progression of keratoconus, the treatment is cytotoxic to the cornea. The combination 
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of riboflavin and UVA light is toxic to both keratocytes and endothelial cells in the 
cornea[45, 46]. Keratocytes are present throughout the entire corneal stroma to heal 
wounds, to maintain corneal transparency and to maintain protein content[22, 47]. 
Keratocytes can regenerate in human. The endothelium regulates the amount of water 
entering the corneal stroma from the anterior chamber. Damage to this layer leads to 
swelling of the cornea resulting in corneal haze, and it causes the cornea to lose its 
refractive function. A corneal transplant is required to restore vision. Unlike keratocytes, 
endothelial cells do not regenerate in human. Therefore, the treatment was carefully 
designed to restrict toxicity to the anterior 340 μm to protect the endothelial cell layer[48-
50]. Damage to keratocytes leads to corneal haze for weeks to months after the surgery[43, 
51]. Repopulation of keratocytes begins 2-3 months after the procedure and completes 
after 6 months[50, 52, 53]. The haze persists in 8.6% of patients[54] resulting in impaired 
vision. 
 Building on the success of Wollensak, Seiler, Spoerl et al., we explore photo-activated 
treatments of keratoconus, post-LASIK ectasia, and degenerative myopia that add 
therapeutic cross-links to the tissues. We diverge from Wollensak et al. in selecting a 
sensitizer that minimizes cytotoxic effects. Mattson[7] has demonstrated that 
photosensitizer eosin Y is effective in strengthening of the cornea and the sclera. Eosin Y 
has a maximum absorption at 514 nm (green) (Figure 1.5). In addition, eosin Y has been 
approved by the FDA for use in the body as part of a lung and dural sealant 
(FocalSeal)[55, 56]. Eosin Y has also demonstrated biocompatibility in a range of 
applications (Table 1.1). In order to assess if eosin Y can produce a treatment that is both 
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effective and safe, it is necessary to determine the stability of the cross-links formed, the 
extent of cross-linking activated, and treatment biocompatibility. 
Table 1.1. Eosin Y biocompatibility  
Authors Application 
Alleyne et al.[55]  Dural Sealant in Canine Craniotomy 
Nakayama et al.[57] Hemostatis of Liver Tissue 
Orban et al.[58] Cardiovascular Applications 
Cruise et al., Pathak et al. 
Desmangles et al.[59-61]  
Islet Cell Encapsulation/ 
Microencapsulation 
Elisseeff et al.[62] Transdermal Polymerization 
Luman et al., Carnahan 
et al.[63, 64] 
Close linear corneal incision, Secure 
Lasik flaps 
West et al.[65, 66]  Thrombosis Inhibition 
(Reproduced from Mattson[7]) 
 
             
  a)  
 
 
 b)       
       
  c)  
 
   
 
  
  d) 
 
 
 
 
 
Figure 1.5. a) Eosin Y is a visible light activated cross-linker. b) Treatment involves 
removing the epithelial cell layer, b) applying a viscous gel containing eosin Y onto the 
cornea, c) irradiating the cornea. (Images c & d adapted from Mattson[7]) 
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1.6 THESIS OUTLINE 
Treatment efficacy relies on stability of the cross-links formed, the extent and the 
distribution of cross-linking induced in the tissue. Stability of the cross-links depends on 
the reaction pathways leading to their formations. Chapter 2 investigates the reaction 
pathways of photodynamic cross-linking in collagen gel. Both riboflavin/UVA and eosin 
Y/visible light cross-link collagen via the singlet oxygen reaction pathway producing 
cross-links that are stable. The extent of cross-linking in the tissue depends on the 
reaction rate, which is a function of the local drug concentration and local light intensity 
at each depth in the tissue. Chapter 3 examines how different cross-linking conditions 
affect collagen cross-linking efficacy in collagen gels with a uniform drug concentration. 
There is an optimal photosensitizer concentration for cross-linking. In the tissue, the drug 
concentration profile resulting from topical delivery depends on the transport properties 
of the tissues. Chapter 4 studies the transport properties of the cornea and sclera. 
Quantification of the amount of drug delivered as a function of time and together with a 
diffusion model, the partition coefficient and diffusion coefficient were determined. 
Different drug delivery techniques to the cornea were assessed to establish a protocol for 
clinical use. A viscous gel formulation consisting of carboxymethylcellulose is the most 
suitable method for topically delivering drug to the cornea. Chapter 5 combines kinetics 
data and transport calculations to predict the cross-linking profile as a function of tissue 
depth for a given set of treatment parameter (drug concentration, drug contact time, delay 
time between the end of drug contact time to the beginning of irradiation period, 
irradiation intensity and duration). The model provides a tool for optimizing treatment 
parameters. Insights from the model were used to design treatments to assess efficacy and 
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safety in a rabbit model. Chapter 6 establishes efficacy by treating rabbit eyes in vitro and 
in vivo, and then tissue stability was determined ex vivo by an intact globe expansion 
method. Eosin Y/visible light treatment produces equivalent stabilization in the cornea 
and induces much less cytotoxicity compared to riboflavin/UVA.   
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Chapter 2 
Reaction Pathways for Photodynamic Collagen  
Cross-linking 
 
2.1 INTRODUCTION 
There has been great interest in photodynamic protein cross-linking due to the wide range 
of photodynamic applications. In some photodynamic applications, the aims are not to 
cross-link proteins but to rely on such mechanisms to achieve the desired outcome. 
Examples of such applications include photodynamic therapies for cancer (aim to kill 
cancer cells)[1, 2] and the photodynamic therapy for macular degeneration (aims to create 
vessel occlusions by damaging the neovascular endothelial cells)[3]. In other 
photodynamic applications, the cross-links themselves contribute to the desired effects. 
Examples of such applications include tissue engineering applications[4, 5] and 
modification of tissue strength[6, 7], which aim to increase material strength by inserting 
protein cross-links. Various proteins undergo covalent cross-linking when irradiated with 
light in the presence of a photosensitizer[8-10]. There are two major photosensitization 
pathways: type I or direct reaction pathway and type II or indirect reaction pathway. 
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These photodynamic reactions begin with the photosensitizer absorbing light which 
transitions the molecule from its ground state to an excited state. In type I, the 
photosensitizer in this excited state reacts with the protein molecule by hydrogen or 
electron transfer[11]. In type II, the photosensitizer in its excited state transfers its energy 
to ground state molecular oxygen to produce singlet oxygen. This highly reactive singlet 
oxygen species then oxidizes the protein[11]. Photosensitization reactions can occur via 
both type I and type II pathways at the same time. The relative contribution of the two 
pathways depends on the sensitizer, protein, solvent composition, and other experimental 
conditions[12, 13]. Here, we are interested in the photodynamic cross-linking therapy for 
enhancing weakened ocular tissues, particularly for diseases including keratoconus [14, 15], 
post-LASIK ectasia[16, 17], and degenerative myopia[18, 19]. Therefore, we give particular 
attention to collagen cross-linking and examine the role of type I and type II reaction 
pathways in the case of two drug/irradiation systems of interest for therapeutic cross-
linking: riboflavin/UVA and eosin Y/visible. 
Pioneering work of Wollensak, Seiler, Spoerl, et al. has led to the development of a 
corneal cross-linking treatment for keratoconus[20, 21]. Cross-linking the corneal stroma 
strengthens the tissue and halts progression of the disease. Cross-linking is achieved by 
activating riboflavin with UVA light (370 nm irradiation). Collagen cross-links formed 
by riboflavin/UVA are stable to chemical, heat, and enzymatic treatment[22]. Because the 
addition of cross-links both enhances tissue strength and provides protection from 
enzymatic degradation, the treatment stabilizes the cornea both by reinforcing the protein 
present at the time of treatment and by reducing the rate of protein turnover that is the 
underlying cause of diseases such as keratoconus and degenerative myopia[19, 23, 24]. 
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Clinical trials for riboflavin/UVA cross-linking therapy lasting up to 5 years have 
demonstrated long-term efficacy. The strengthening effect due to cross-linking observed 
in the cornea is also seen in the sclera[7, 25]. So cross-linking may be able to halt the 
progression of degenerative myopia, which is a disease associated with weakening and 
thinning of the sclera that is a major, untreatable cause of blindness[26].  
The drawbacks of the riboflavin/UVA treatment are due to the toxicity of the 
combination of riboflavin with UVA[27-29]. The treatment induces apoptosis of more than 
90% of the keratocytes in the anterior 400 µm of the corneal stroma[30, 31] and full 
recovery requires up to 12 months in some patients[32]. Of greater concern is the potential 
for endothelial toxicity due to the limited recovery of the human endothelium after injury. 
Consequently, keratoconus patients with corneas thinner than 400 μm are excluded from 
receiving this therapy[30, 31]. To establish a safer cross-linking treatment, we are 
investigating a visible light activated photosensitizer, eosin Y, that produces cross-linking 
in the cornea and sclera at comparable rates to riboflavin/UVA (Chapter 3). 
Biocompatibility studies in the cornea show that eosin Y activated by green light results 
in much lower cytotoxicity than riboflavin/UVA (some keratocytes in the anterior 100 
µm undergo apoptosis, Chapter 6). 
Here we examine the relationship between the reaction pathway that produces cross-
linking in the eosin Y/visible treatment and the reaction pathway of the riboflavin/UVA 
treatment. The extensive literature on photodynamic protein cross-linking reaction 
mechanisms guides the selection of a small set of experiment can lead to a broad set of 
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deductions regarding the chemical reactions that occur in both riboflavin/UVA and eosin 
Y/visible light therapeutic cross-linking treatments.  
Photorheology is used to monitor the rate of cross-linking by measuring the sample’s 
modulus during irradiation. Rates of photo-activated cross-linking of collagen gels are 
compared as a function of the presence of molecular oxygen in the environment and the 
concentration of singlet oxygen quenchers. This provides a simple method of establishing 
the relative importance of type I and type II reaction pathways. 
2.2 METHODS 
Collagen Gel Preparation – A mixture of 2.5 g gelatin from bovine skin (Sigma Aldrich 
G6650 Lot #047K0005) and 6.0 mL Dulbecco’s phosphate buffered saline (DPBS, Sigma 
D8662) was heated at 75°C for 30 ± 1 minutes to dissolve all the gelatin. After the gelatin 
solution was removed from the heat bath, 1 mL of 0.5% riboflavin-5′-monophosphate 
(riboflavin, Sigma Aldrich R7774) or 1 mL of 0.2% eosin Y (Sigma Aldrich E6003 Lot# 
022K3692) solution, and  0.5 mL of a quenching reagent (sodium azide or ascorbic acid) 
stock solution having 20 times the final desired concentration were added to the gelatin 
solution. The solution was swirled for a few seconds to yield a uniform final mixture 
containing 25% w/w gelatin, 0.05% riboflavin or 0.02% eosin Y, and the desired 
quencher concentration. Two quenching conditions were examined: 100 mM sodium 
azide and 20 mM ascorbic. 
To produce a uniform layer of gel, a mold was prepared using a Teflon spacer between 
two Plexi-glass plates, which were held together with clamps (Figure 2.1a). The Teflon 
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spacer provided a controlled gap to form 500 μm thick gels. Prior to dispensing the 
solution into a mold, both the glass Pasteur pipette and the gel mold were warmed using a 
heat gun (for ~15 seconds). The warm solution was then dispensed into the warm mold; 
then the filled mold was wrapped in aluminum foil to prevent dehydration and interaction 
with light. The gel mold was stored at ~4°C for at least 8 hours to form a solid gel. This 
procedure was used to create eosin Y and riboflavin gels with varying quencher 
concentrations. All samples were measured within 48 hours of the beginning of gel 
preparation. 
 
a) 
 
b) 
 
Figure 2.1. a) Forming a gel in a mold made of two Plexi-glass plates and a Teflon 
spacer all held together by clamps. b) A schematic of the photorheology set up for 
measuring real-time changes in sample modulus. The chamber with the sponge and water 
at the top sealed off by a cap prevented sample dehydration. LEDs below the quartz 
window provided light for sample irradiation. The gas inlet provides the option to create 
an oxygen free environment inside the chamber. 
 
Photorheology Apparatus – Collagen gel photorheology was performed on a stress-
controlled shear rheometer (TA Instrument AR1000). The lower, stationary tool was 
modified to deliver light to the sample. A custom-built light delivery device was mounted 
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onto the Peltier plate of the rheometer (Figure 2.1b) similar to those described by Khan, 
Plitz, et al.[33] (TA Instrument has similar UV LED accessories for the rheometer). The 
lower plate was replaced with an aluminum plate with a 50-mm diameter quartz window 
positioned at the center allowing the transmission of both visible and ultraviolet (UV) 
light. Irradiation was achieved by placing a cluster of four light emitting diodes directly 
below the quartz window; two different LED clusters were constructed, one using 
Luxeon Star LXML-PM01-0080 at 530 ± 15 nm for irradiating gels containing eosin Y 
and the other using Roithner Lasertechnik UVLED-365-250-SMD at 370 ± 12 nm to 
irradiate gels containing riboflavin. To maintain the LED cluster at a steady operating 
temperature, it was mounted on an aluminum heat sink attached to a tube that provided a 
steady flow room temperature air over the heat sink. During irradiation, the light intensity 
3 mW/cm2 with 370 nm light for riboflavin samples and 6 mW/cm2 with 525 nm light for 
eosin Y samples controlled by adjusting the input voltage provided by a power supply 
(Hewlett Packard E3620A). The intensity profile as a function of position at the top of the 
quartz window was characterized using a fiber optic with “cosine corrector” (Ocean 
Optics Jaz) and was found to vary less than 5% from the value at the center of the 8-mm 
diameter sample area.  
Oscillatory Shear Storage Modulus Measurement – A circular sample 8-mm in diameter 
was cut from the gel sheet. The sample was placed onto the upper tool (8-mm aluminum 
parallel plate) to ensure proper alignment. Then the upper tool was lowered to bring the 
sample in contact with the lower plate. The normal force reading began to register at a 
gap thickness that was consistent with the spacer’s thickness (within 2%).  To ensure 
good contact between the specimen and the tools, the gap was reduced to 90% of the 
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nominal sample thickness with typical initial normal force registering ~2 N. To prevent 
gel dehydration, the sample was enclosed in a chamber containing a wet sponge that kept 
surrounding environment saturated with water vapor (Figure 2.1b). The chamber also had 
an inlet for gas flow so that the chamber’s environment could have oxygen present or 
absent by purging the chamber with air or argon, respectively.    
The temperature of the sample was maintained at 24 ± 1ºC (Omega HH059 
thermocouple). Once the sample was in contact with the lower plate, a 15-minute interval 
was allowed for thermal equilibration before the linear storage modulus was measured at 
a frequency of 0.3 rad/s using an oscillatory stress amplitude of 30 Pa (in the linear 
regime). The storage modulus was measured every minute for 50 minutes, including 10 
minutes prior to irradiation (to verify that gelation was complete), 30 minutes during 
irradiation and 10 minutes after cessation of irradiation (to determine if cross-linking 
continued, i.e., if there is significant “dark reaction”). Each condition was repeated at 
least 3 times to obtain the reported mean and standard deviation.  
2.3 RESULTS 
During the 30-minute irradiation period (3 mW/cm2 at 370 nm), the average rate of 
change of the storage modulus, dG'/dt, of riboflavin samples was 27.2 ± 4.7 Pa/min in the 
presence of oxygen (in air) and decreased to being indistinguishable from zero in the 
absence of oxygen (in argon), or by addition of 100 mM sodium azide or 20 mM of 
ascorbic acid (Figure 2.2). Similarly, during irradiation (6 mW/cm2 at 525 nm) of eosin Y 
samples, dG'/dt = 25.8 ± 5.1 Pa/min in air and indistinguishable from zero in argon 
(Figure 2.2a). In eosin Y samples, singlet oxygen scavengers reduce the rate of change of 
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modulus, but it remains distinguishable from zero in the presence of 100 mM sodium 
azide and 20 mM ascorbic acid. The greater effect of singlet oxygen quenchers on the 
rate of cross-linking in riboflavin samples is reinforced by the low concentration of 
sodium azide that reduces the rate to indistinguishable from zero (as little as 10mM 
sodium azide) and the substantial concentration of ascorbic acid that is required to 
effectively eliminate cross-linking in eosin Y samples (at least 100 mM ascorbic acid). In 
both riboflavin and eosin Y samples, ascorbic acid has a greater inhibitory effect than 
sodium azide. 
 
           
Figure 2.2. Average rate of change in storage modulus during 30-minute irradiation of 
collagen gels containing (left) 0.05% riboflavin (370 nm at 3 mW/cm2) and (right) 0.02% 
eosin Y (530 ± 15 nm at 6 mW/cm2). Four conditions are examined: under air (Treated), 
in the absence of oxygen (Argon), and under air with singlet oxygen quenchers: sodium 
azide (100 mM SA) and ascorbic acid (20 mM AA). The asterisk indicates a statistically 
significant rate that is distinguishable from 0 (p < 0.05). (N = 3 to 12)  
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2.4 DISCUSSION 
 Singlet oxygen mediates collagen cross-linking for both riboflavin and eosin Y –
Riboflavin/UVA clinical treatment for keratoconus relies the formation of protein-protien 
cross-links in the cornea to enhance tissue strength and resist enzymatic degradation[34, 
35]. Although there are contradictory reports in the literature[36], McCall, Kraft, et al.[37] 
found that corneal cross-linking induced by riboflavin/UVA proceeds via the singlet 
oxygen pathway. In accord with McCall et al. the present results indicate that 
riboflavin/UVA cross-linking requires oxygen and that singlet oxygen specifically 
mediates cross-linking (Figure 2.2). 
Collagen cross-linking activated by eosin Y with visible light exhibits very similar 
behavior to riboflavin/UVA. In particular, oxygen is required for cross-linking and the 
addition of singlet oxygen quenchers (sodium azide and ascorbic acid) inhibits cross-
linking (Figure 2.2). This is consistent with the fact that eosin Y generates singlet oxygen 
upon irradiation in the presence of molecular oxygen[38, 39], and that eosin photosensitized 
cross-linking of peptides mainly occurs through a process mediated by singlet oxygen[40].  
Thus, the photosensitized cross-linking reactions for both riboflavin/UVA and eosin 
Y/visible proceed via the singlet oxygen pathway. It has been demonstrated that 
photodynamic reactions proceeding through the singlet oxygen pathway yield similar 
chemical modifications even when different sensitizers are used[41-43]. Based on this 
understanding, it is expected that the cross-links formed by eosin Y/visible light should 
be equivalent to the stable ones formed by riboflavin/UVA light. Collagen cross-links 
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induced by riboflavin/UVA are stable to chemical, heat, and enzymatic degradation, 
providing treatment efficacy that lasts for years[22]. 
Importance of histidine, arginine and lysine in collagen cross-linking by singlet oxygen –
Considerable molecular insight into corneal collagen cross-linking can be gained by 
considering the literature on the reactions of singlet oxygen and proteins. Motivated by 
the importance of protein-protein cross-linking in aging, photodynamic therapy and tissue 
engineering, extensive studies have examined cross-linking induced by singlet oxygen in 
crystallins[9, 44, 45], ribonuclease A[10], spectrin[46], fibrin[47], fibrinogen[47], and collagen[48]. 
Photo-oxidation of susceptible amino acids is the primary photodynamic process; 
subsequent covalent cross-linking occurs via secondary, light independent reactions[12, 49]. 
There are only five amino acids that are susceptible to photo-oxidation: tryptophan, 
tyrosine, cysteine, methionine and histidine[13, 50, 51]. These photo-oxidized adducts of 
these amino acids can react with other amino acids; and some of these reactions produce 
covalent cross-links.  
In relation to therapeutic cross-linking, the relative importance of each of the five photo-
oxidizable amino acids can be evaluated based on their relative reactivity with singlet 
oxygen, their propensity to produce cross-links, and their relative abundance in the 
predominant protein present in the cornea and sclera—collagen type I (Table 2.1). While 
the amino acids that are very reactive with singlet oxygen are tryptophan and cysteine[52, 
53], neither of these is present in collagen type I[54]. While methionine is reactive toward 
singlet oxygen and is present in collagen type I, it does not participate in the cross-linking 
reactions[10, 12, 55]. While tyrosines can be photo-oxidized to form cross-links[12, 36], the 
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presence of oxygen actually inhibits tyrosine modification and cross-linking (it occurs 
through a type I reaction pathway)[8, 36]. Furthermore, dityrosine formation was not 
observed in the cross-linking process mediated by singlet oxygen in proteins, peptides, or 
model tyrosine copolymers[10, 55, 56]. Therefore, among the five photo-oxidizable amino 
acid residues, tryptophan, cysteine, methionine, and tyrosine are not expected to be 
significant in the corneal and sclera cross-linking induced by the photosensitizers in this 
study. Therefore, we direct our attention to histidine. 
 
 
Table 2.1. Rate constants for chemical reactions 
between singlet oxygen and photo-oxidizable 
amino acids and the quantity of each amino found 
in collagen type I. 
Amino acid 𝒌 𝑶𝟐𝟏  x 10
-7 M-1s-1 Mole %  
Tryptophan 1.3-3 0 
Cysteine 0.89 0 
Methionine* 1.6 0.5 
Tyrosine# 0.8 0.4 
Histidine 3.2-3.4 0.6 
*Methionine is not known to produce cross-links 
#Tyrosine cross-linking is inhibited by oxygen 
 
Table 2.2. The quantity of 
amino acid containing amine 
group(s) present in collagen 
type I. 
Amino Acid Mole % 
Glutamine 0 
Asparagine 0 
Arginine 4.7 
Lysine 2.8 
 
 
 
Photo-oxidation of histidine via a singlet oxygen mediated process has been examined in 
free histidine amino acid[12, 42, 52, 57], histidine model compounds[10, 51], histidine in 
peptides[40, 52] and proteins[9, 10, 46, 55, 58]. Photo-oxidation of histidine can lead to cross-
linking. Studies using rose bengal as a photosensitizer found histidine residues are 
necessary for cross-linking; blocking the histidine residues leads to a decrease in cross-
link formation in crystallin[9] and ribonuclease A[9, 10]. Even though crystallin also 
II-12 
 
contains tryptophan and tyrosine and ribonuclease A also contains tyrosine, methionine, 
and cysteine, these amino acids have negligible roles in cross-linking mediated by singlet 
oxygen. Proteins without histidine (e.g. melittin and bovine pancreatic trypsin inhibitor) 
do not form cross-links in the presence of singlet oxygen[10]. Although the exact 
mechanism of cross-linking involving histidine is not well understood, cross-linking 
appears to occur through interaction between the photo-oxidized histidine and an amine 
group[10, 12, 40, 46, 55] or with another histidine[43, 51]. Model copolymers containing histidine 
can form photodynamic cross-links with other copolymers containing lysine[51] or 
histidine[43, 51] through the singlet oxygen pathway. Protecting the amine groups in protein 
inhibits photodynamic cross-linking[10, 43, 55].  
Of the four amino acid residues that contain amine group(s), only two are present in 
collagen type I (Table 2.2). Based on their high abundance in collagen type I, a photo-
oxidized histidine is most likely to react with an arginine or lysine. The specific rates of 
cross-linking reactions depend on the proximity of one of these amino acids to a photo-
oxidized histidine and the degree of “exposure” of the side chains for reaction[13].  
Peroxidic species are intermediate products in photodynamic cross-linking – Photo-
oxidation of tryptophan and tyrosine residues has been investigated, establishing the 
structures of the peroxides intermediates formed and of some of their decomposition 
products[59-63]. However, tryptophan is not present in type I collagen; and tyrosine 
produces cross-links via a type I mechanism, which appears to be negligible in 
riboflavin/UVA and eosin Y/visible photodynamic cross-linking. Unfortunately, there is 
scant literature regarding the oxidation mechanism of histidine (or related compounds) in 
II-13 
 
aqueous media at physiological pH. Photolysis of N-benzoyl-His has been examined 
under basic conditions (pH 11), such that the imidazole ring is susceptible to nucleophilic 
attack (leading to formation of urea, N-benzoyl-Asp and N-benzoyl-Asn)[64, 65]. Oxidation 
of substituted imidazole derivatives in organic solvents gives rise to peroxidic species[66], 
which have been hypothesized to be intermediates in subsequent reactions, such as cross-
linking of oxidized amino acids with unmodified residues[12, 43, 51].  
Davies et al.[67] have performed the most thorough examination to date of the reactions of 
singlet oxygen with histidine, including comparison of multiple sensitizers and various 
histidine derivatives (free His amino acid, model compounds, and His in a peptide), 
examining the lifetimes and subsequent reactions of the peroxides that form, and solving 
the structures of some of the major photo-products. They performed detailed structural 
analysis of the radicals and relatively stable intermediate products formed via reactions of 
singlet oxygen with His, N-Ac-His, imidazole, 4(5)-methylimidazole and 3-(Imidazol-4-
yl)propionic acid (IPA).  
Using these solved structures, they searched for analogous adducts in a simple tripeptide, 
Gly-His-Gly (GHG), subjected to the same photo-oxidation conditions. Analysis of the 
reaction products by HPLC/MS revealed three fractions that could be resolved from GHG 
by HPLC, which differed in mass by the addition of two, three and five oxygen atoms, 
respectively; in contrast, only two added oxygens were present in the structures formed 
upon photo-oxidation of the model compounds. NMR spectra of the crude photo-
oxidized-GHG solutions gave “weak, unidentified signals;” comparison with the spectral 
features of the established products of photo-oxidation of simpler compounds revealed no 
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evidence for the formation of analogous species.  Davies speculates that peptide bond 
formation deactivates the lone pair on the nitrogen of the α-amino group, giving 
histidines in proteins a different reaction profile than the model compounds. To date, the 
structures formed during photo-oxidation of histidine in proteins are not known. 
Potential role of favorable sensitizer-protein interactions – Eosin Y is commonly used as 
a staining agent since it binds to proteins. Its affinity to collagen is observed in how 
favorably it partitions into the cornea and sclera (Chapter 4). Specifically, Waheed et 
al.[68] found that histidine, lysine, and arginine residues bind electrostatically to eosin Y 
to produce a stable, water-soluble protein-dye complex. It is known that protein-binding 
of photosensitizers inhibits quenching of the singlet oxygen they produce during 
irradiation: for example, rose bengal binds to albumin and the addition of sodium azide 
only moderately reduces the rate of photo-oxidation of albumin by rose bengal (in 
contrast to the severely reduced rate observed for peptides that do not bind rose 
Bengal)[69]. A similar effect may be evident in the case of eosin Y bound to collagen 
(preferentially at histidine residues): singlet oxygen quenchers moderately suppress 
photo-oxidation of collagen by eosin Y (in contrast to the severely reduced rate observed 
with a photosensitizer that does not bind to collagen, Figure 2.2). Perhaps binding of 
eosin Y molecules to histidines increases the likelihood that a singlet oxygen generated 
during irradiation encounters a histidine before being quenched by sodium azide or 
ascorbic acid. For riboflavin, no such binding effect is present (Chapter 4), so singlet 
oxygen must diffuse through the quencher solution to reach histidine, consistent with the 
relative ease of preventing cross-link formation using singlet oxygen quenchers.  
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2.5 CONCLUSION 
The present experimental results, along with prior literature, suggest collagen cross-
linking induced by riboflavin/UVA and eosin Y/visible light are both mediated by singlet 
oxygen. In addition, histidine is the most likely amino acid to play a major role in the 
collagen cross-linking reactions in the cornea and sclera. Subsequent reactions with the 
photo-oxidized histidine residue are likely to involve an arginine, lysine, or another 
histidine. Cross-links formed via this pathway are found to be stable to chemical 
treatment using 2-mercaptoethanol, heat treatment by boiling in water for five minutes, 
and enzymatic degradation by pepsin[22]. These cross-links generated by riboflavin/UVA 
are found to be stable in the cornea for at least 5 years[20], and since eosin Y generates 
cross-links via the same reaction pathway they should be stable as well.  
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Chapter 3 
Collagen Cross-linking Kinetics 
 
3.1 INTRODUCTION 
Keratoconus is a corneal ectasia associated with progressive corneal thinning and 
protrusion resulting in a conical shaped cornea. This disease has a prevalence of 1 in 
2,000 with no race or gender bias[1]. Pioneering research of Wollensak, Seiler, and Spoerl 
demonstrated that photodynamic corneal collagen cross-linking using riboflavin and 
UVA can halt the progression of keratoconus[2]. The concept underlying the treatment is 
revolutionary, however, the phototoxicity of riboflavin and UVA results in certain 
limitations and drawbacks. The combination of riboflavin and UVA is toxic to both 
keratocytes and endothelial cells[3, 4]. The endothelium is responsible for maintaining 
corneal transparency and the cells do not regenerate in humans. Therefore, the treatment 
parameters (riboflavin concentration, duration of drug delivery prior to irradiation and 
frequent reapplication of riboflavin during irradiation) are carefully designed to restrict 
toxicity to the anterior 350 µm of the stroma[5].   
In the current clinical protocol, topical application the drug solution (0.1% riboflavin with 
20% dextran) to the cornea is repeated every 2 minutes for 30 minutes before irradiating, 
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and every 5 minutes during the 30 minute irradiation with 3 mW/cm2 UVA. The high 
riboflavin concentration is necessary to prevent significant UVA light from penetrating 
more than 350 µm. Thirty minutes of topical application prior to irradiation is required to 
establish the protective riboflavin concentration in the stroma[5]. The treatment cannot be 
used with corneas under 400 µm because it then results in “significant necrosis and 
apoptosis of endothelial cells”[4]. Almost all of the keratocytes in the anterior 300-350 µm 
of the stroma undergo apoptosis, which results in corneal edema[3, 6-8]. The resulting 
stromal haze persists for weeks to months after treatment; full recovery of the keratocyte 
population requires 6 to 12 months[8, 9].  
To retain the benefits of corneal cross-linking and reduce the toxicity of the treatment, it 
has been suggested that a photosensitizer that is activated by visible light might be 
used[10]. In vitro results suggest that Eosin Y (a photosensitizer with an absorption peak at 
514 nm) can produce cross-linking in the cornea (Chapter 6) and sclera[11], comparable to 
riboflavin/UVA treatment. Eosin Y has been approved by the US-FDA for use in the 
body[12]. Safety studies of eosin Y activated by green light in a rabbit model show little 
keratocyte apoptosis, using eosin Y concentration and irradiation conditions that produce 
comparable cross-linking to the riboflavin/UVA treatment for keratoconus (Chapter 6). 
No endothelial toxicity was observed with eosin Y/visible light, opening the way to 
treating patients whose cornea is less than 400 µm thick due to advanced keratoconus or 
other conditions, such as post-LASIK ectasia[13]. In relation to the application of collagen 
cross-linking to treat degenerative myopia[14, 15], in vivo studies of eosin Y activated by 
visible light showed no retinal toxicity in a guinea pig model[11], in contrast to early in 
vivo results with riboflavin/UVA[4].  
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Here we examine the relative rates of cross-linking produced by both the clinical therapy 
(riboflavin/UVA) and the pre-clinical therapy (eosin Y/visible light). The rate of change 
of the apparent shear modulus is measured as a function of photosensitizer concentration 
and irradiation intensity using photorheology, which is widely used to study 
photopolymerization kinetics[16-18]. Collagen gel is used as a substrate because of its 
excellent uniformity and reproducibility.  
3.2 METHODS 
Collagen Gel Preparation – Similar method used in Chapter 2 was used for preparing 
gel. Briefly, a mixture of 2.5 g gelatin from bovine skin and 6.5 mL dulbecco’s phosphate 
buffered saline (DPBS) was heated at 75°C for 30 ± 1 minutes to dissolve all the gelatin. 
After the gelatin solution was removed from the heat bath, 1 mL of an eosin Y or 
riboflavin stock solution having 10 times the final desired concentration was added to the 
9 mL gelatin solution. The final mixture contained 25% w/w gelatin and the desired 
concentration of eosin Y or riboflavin. Six concentrations of eosin Y (0.005, 0.01, 0.02, 
0.04, 0.1 and 0.2%) and 8 concentrations of riboflavin (0.005, 0.01, 0.03, 0.05, 0.07, 0.1, 
0.3, and 0.5%) were examined as well as controls without photosensitizers.  
To produce a uniform layer of gel, a mold was prepared using a Teflon spacer between 
two Plexi-glass plates, which were held together with clamps (Figure 3.1a). The Teflon 
spacer provided a controlled gap with the desired gel thickness; four spacer thicknesses 
were used (250, 500, 1000 and 1500 µm). The warm solution was dispensed into the 
warm mold; then the filled mold was wrapped in aluminum foil to prevent dehydration 
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and stored at ~4°C for at least 8 hours to form a solid gel. All samples were measured 
within 48 hours of the beginning of gel preparation. 
 
a) 
 
b) 
 
Figure 3.1. a) Forming a gel in a mold made of two Plexi-glass plates and a Teflon 
spacer all held together by clamps. b) A schematic of the photorheology set up for 
measuring real-time changes in sample modulus. The chamber with the sponge and water 
at the top sealed off by a cap prevented sample dehydration. LEDs below the quartz 
window provided light for sample irradiation.  
 
Photorheology Apparatus – The same apparatus was used as in Chapter 2. Briefly, 
Collagen gel photorheology was performed on a stress-controlled shear rheometer (TA 
Instrument AR1000). The lower, stationary tool was modified to deliver light to the 
sample. The lower plate was replaced with an aluminum plate with a 50-mm diameter 
quartz window positioned at the center allowing the transmission of both visible and 
ultraviolet (UV) light. The light intensity (0-6 mW/cm2) was controlled by adjusting the 
input voltage (0-16 V) provided by a power supply. The intensity profile as a function of 
position at the top of the quartz window was found to vary less than 5% from the value at 
the center of the 8-mm diameter sample area.  
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Oscillatory Shear Storage Modulus Measurement – An 8-mm diameter sample was cut 
from the gel sheet. The sample was placed onto the upper tool (8-mm aluminum parallel 
plate) to ensure proper alignment. Then the upper tool was lowered to bring the sample in 
contact with the lower plate. To ensure good contact between the specimen and the tools, 
the gap was reduced to 90% of the nominal sample thickness. To prevent gel dehydration, 
the sample was enclosed in a chamber containing a wet sponge that kept surrounding air 
saturated with water vapor (Figure 3.1b).  
The temperature of the sample was maintained at 24 ± 1ºC (Omega HH059 
thermocouple).  Once the sample was in contact with the lower plate, a 15-minute 
interval was allowed for thermal equilibration before the linear storage modulus was 
measured at a frequency of 0.3 rad/s using an oscillatory stress amplitude of 30 Pa (in the 
linear regime). The storage modulus was measured for 50 minutes, including 10 minutes 
prior to irradiation (to verify that gelation was complete), 30 minutes during irradiation 
and 10 minutes after cessation of irradiation (to determine if cross-linking continued, i.e., 
if there is significant “dark reaction”). Each condition was repeated at least 3 times to 
obtain the reported mean and standard deviation.  
3.3 RESULTS 
The initial modulus was in the range of 3610 ± 760 Pa and, during the ten minutes prior 
to irradiation, G' typically decreased slightly, by 50 to 200 Pa (see Appendix for 
individual G' curves). The change of the storage modulus G' during and after irradiation 
relative to its value at the beginning of irradiation (i.e., end of the first ten minutes, G'10) 
is  
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 ∆G′ =   G′t  −  G′10 Equation 1 
   
 
where G't is the modulus at time t. For example, the storage modulus of a sample 
containing 0.02% eosin Y increased 793 ± 118 Pa while exposed to 6 mW/cm2 at 530 ± 
15 nm (Figure 3.2a). A similar change in modulus (819 ± 85 Pa) was observed in the 
gelatin containing 0.1% riboflavin sample over the 30-minute irradiation with 3 mW/cm2 
at 370 ± 12 nm (Figure 3.2b).   
 
a) 
 
b) 
 
Figure 3.2. Change in storage modulus where ∆G' = G't - G'10 as a function of time for 
450 µm thick gel samples with a) eosin Y and b) riboflavin. Samples containing eosin Y 
were irradiated with green light at 530 ± 15 nm and those containing riboflavin were 
irradiated with UV light at 370 ± 15 nm. The presence of both drug and light are 
necessary for enhancing the storage modulus. (N = 3 to 6)  
 
Negligible modulus change was observed over the 30-minute period in controls that 
either received no light or that contained no sensitizer: without irradiation ∆G' was -23  ± 
76 Pa for (0.02% eosin Y, 0 mW/cm2) and 72 ± 136 Pa for (0.1% riboflavin, 0 mW/cm2); 
and without sensitizer ∆G' was -125 ± 80 Pa for (0% eosin Y, 6 mW/cm2) and -74 ± 95 
Pa for (0% riboflavin, 3 mW/cm2). This demonstrates that both sensitizer and irradiation 
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are necessary to produce the collagen cross-linking that underlies the increase in the 
storage modulus.  
During the 10 minutes after cessation of irradiation, the modulus changes were small and 
indistinguishable (p-values were > 0.05 for all conditions with respect to the average of 
all of them together) for all six conditions: 61 ± 136 Pa for (0.02% eosin Y, 6 mW/cm2), 
59 ± 34 Pa for (0.02% eosin Y, 0 mW/cm2), 84 ± 34 Pa for (0% eosin Y, 6 mW/cm2), 70 
± 19 Pa for (0.1% riboflavin, 3 mW/cm2), 32 ± 36 Pa for (0.1% riboflavin, 0 mW/cm2), 
and 112 ± 30 Pa for (0% riboflavin, 3 mW/cm2).  Therefore, negligible cross-linking 
occurs after cessation of irradiation in either system.  
Since the presence of both drug and light are necessary for enhancing the gel’s modulus, 
it is of interest to examine how each of these two factors affects the rate of change of G'. 
The rate of increase was nearly constant throughout the irradiation period. Therefore, the 
rate of change of G', denoted dG'/dt, was estimated by simply dividing the overall change 
in G' during irradiation by the irradiation time: 
 
 𝑑𝐺′
𝑑𝑡
= 𝐺′�𝑡𝑓� − 𝐺′(𝑡𝑖)
𝑡𝑓 − 𝑡𝑖
 Equation 2 
 
 
where ti = 10 minute and tf = 40 minutes correspond to the beginning and the end of the 
irradiation period. At a given photosensitizer concentration and sample thickness, the 
cross-linking rate (manifested by dG'/dt) increases monotonically with irradiation 
intensity for both eosin Y and riboflavin, approaching a plateau rate (Figure 3.3a). 
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For a fixed sample thickness that is similar to the thickness of the cornea (450 µm) and a 
light intensity that saturates the cross-linking rate (6 mW/cm2 for eosin Y and 3 mW/cm2 
for riboflavin), there is a distinct maximum in dG'/dt as a function of photosensitizer 
concentration for both eosin Y and riboflavin. The peak values are similar for the two 
sensitizers (dG'/dt max = 27 ± 4.1 Pa/min for eosin Y, and dG'/dt max = 33 ± 4.6 Pa/min for 
riboflavin). The optimal concentrations, 0.02% eosin Y and 0.05% for riboflavin, 
correlate with the molar absorptivity of the two compounds (below). The shapes of the 
peaks in dG'/dt as a function of concentration are very similar for eosin Y and riboflavin. 
For a photosensitizer concentration near the optimal value for a 450 µm thick specimen, 
dG'/dt decreased with increasing sample thickness over the range from 225 to 1350 µm 
for both eosin Y and riboflavin (Figure 3.3c).   
 
a) 
 
b) 
 
c) 
  
Figure 3.3. Rate of change of the apparent storage modulus a) as a function of irradiation 
intensity at a fixed sample thickness (450 μm) and fixed photosensitizer concentration 
(0.02% eosin Y, 0.1% riboflavin) b) as a function of photosensitizer concentration at 
fixed sample thickness (450 μm) and fixed irradiation intensity (6 mW/cm2 for eosin Y, 3 
mW/cm2 for riboflavin) and c) as a function of sample thickness at fixed photosensitizer 
concentration (0.02% for eosin Y and 0.1% for riboflavin) and irradiation intensity (6 
mW/cm2 for eosin Y and 3 mW/cm2 for riboflavin). Samples containing eosin Y were 
irradiated with green light at 530 ± 15 nm and those containing riboflavin were irradiated 
with green light at 370 ± 12 nm. (N = 4 to 14) 
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3.4 DISCUSSION 
Collagen gel photorheology can be used to efficiently characterize the effects of 
irradiation intensity, photosensitizer concentration, and sample thickness on the rate of 
collagen cross-linking. Consistent with previous results, collagen can be cross-linked in 
the presence of a photosensitizer (e.g. riboflavin[19-21], eosin Y[22, 23], rose bengal[19, 24-26], 
methylene blue[27], and brominated 1,8-naphthalimide[28]) upon irradiation and no cross-
linking was observed in the absence of either the sensitizer or irradiation[25, 26].  
Collagen cross-linking can also be achieved through non-photo-activated chemical or 
physical techniques. Chemical agents such as glutaraldehyde and formaldehyde are very 
effective in cross-linking collagen but they are cytotoxic[25, 26]. Other chemical agents 
such as carbodiimide and its derivatives are more biocompatible but the reactions are 
very slow[25]. Collagen cross-linking with physical techniques such as heat, UV 
irradiation, and gamma irradiation do not form stable cross-links[26]. Photo-activated 
cross-linking has been demonstrated to be biocompatible[19, 26]. Using photo-activated 
molecules decouples reaction and diffusion and confers spatial control of cross-linking. 
Diffusion can occur, then reaction can be initiated by light. Treatment can be targeted to 
specific locations by delivering the drug and then irradiating selected locations to avoid 
cross-linking adjacent tissues which can lead to adverse effects. Light activation of the 
drug also enables control over the depth of cross-linking inside the tissue. The 
photosensitizing drug can be delivered then allowing time for diffusion to achieve a 
desirable drug concentration profile before irradiating. In addition, the use of light 
activation also enables control over the extent of cross-linking by selecting irradiation 
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parameters (intensity and duration). Photo-activated corneal cross-linking efficacy 
depends on the collagen cross-linking rate.  
The non-monotonic concentration dependence of photo-activated reactions is well known 
in systems ranging from photodynamic therapy to curing polymers via 
photopolymerization[29-32]. The optimal concentration reflects the trade-off between the 
number of sensitizer molecules present and the attenuation of light by the sensitizer: at 
low concentration, the reaction is limited by the amount of photosensitizer present; 
beyond the optimal concentration, the reaction is limited by the penetration depth of the 
irradiation.   
The fraction of the sample that receives irradiation of the order of that incident on its 
surface is characterized by Λ, the ratio of the optical penetration depth (Lp, at which the 
intensity has been attenuated by 1/e) to the sample thickness (L), which decreases with 
increasing photosensitizer concentration in the sample: 
 
 
𝛬 = 𝐿𝑝
𝐿
 Equation 3 
 
 
The light intensity profile in a sample with uniform concentration C of photosensitizer is 
given by: 
 𝐼(𝑧) = 𝐼𝑜𝑒−(𝜇+𝐶𝜀)𝑧 Equation 4 
   
 
where I(z) is the intensity at depth z, Io is the incident intensity, µ is the sample’s 
absorptivity, and ε is the photosensitizer’s molar absorptivity. The normalized cross-
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linking rate characterized by (dG'/dt)/( dG'/dt)max initially increases as Λ increases by 
decreasing concentration at fixed sample thickness until more than half the thickness of 
the sample receives intensity greater than Io/e (i.e., until Λ > ½), where a maximum rate 
occurs at approximately Λmax = 0.6 to 0.7 for both eosin Y and riboflavin (Figure 3.4a). 
Beyond Λmax the rate decreases with increasing Λ, reflecting the loss of efficacy at low 
sensitizer concentration. When Λ is increased by decreasing sample thickness, 
 (dG'/dt)/( dG'/dt)max increases until it saturates at the value associated with uniform light 
intensity throughout the sample. 
 
a) 
   
b) 
 
Figure 3.4. Normalized rate of change in modulus (dG'/dt)/( dG'/dt)max as a function of 
the normalized optical penetration depth evaluated using a)  data obtained with a fixed 
sample thickness (450 µm, Figure 3.3b) and  b) data obtained using a fixed 
photosensitizer concentration (0.02% eosin Y and 0.1% riboflavin, Figure 3.3c). Eosin Y 
samples were irradiated with 530 ± 15 nm light at 6 mW/cm2 and riboflavin samples 
were irradiated with 370 ± 12 nm light at 3 mW/cm2. (N = 4 to 14) 
 
The keratoconus treatment protocol approved for clinical use in Europe and undergoing 
clinical trials in the United States uses 0.1% riboflavin concentration and 3 mW/cm2 at 
370 nm. The drug is applied topically every 2 minutes for 30 minutes followed by UV 
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irradiation for 30 minutes while applying drops every five minutes. Using the riboflavin 
diffusion coefficient (D = 79 µm2/s) obtained in Chapter 4, the concentration profile after 
30 minutes of drug application yields a relatively uniform concentration throughout the 
thickness of the cornea, similar to the situation in the collagen gel experiments. Using the 
riboflavin partition coefficient (k = 1.7) obtained in Chapter 4, the average concentration 
of riboflavin in the cornea is predicted to be 0.12% (varying from 0.17% at the anterior 
surface to 0.06% at the posterior surface, Figure 3.5a). In collagen gel samples with 0.1% 
riboflavin, the rate increases with intensity up to 3 mW/cm2 and then saturates (Figure 
3.3a). Thus, the clinical irradiation intensity (3 mW/cm2) corresponds to the lowest value 
which induces the highest cross-linking rate. The clinical protocol uses a riboflavin 
concentration that is not optimal (by interpolation, 0.12% riboflavin concentration yields 
a cross-linking rate that is approximately 78% of the optimal rate that would be achieved 
using 0.05% riboflavin, see Figure 3.3b). The selection of a greater-than-optimal 
concentration of riboflavin may be due to the toxicity of riboflavin and UVA light: the 
riboflavin concentration is chosen based on the need to attenuate UVA light to a safe 
level, protecting the endothelium in patients with stromal thickness greater than 400 µm[2, 
4, 9, 33]; patients with stromal thickness less than 400 µm are excluded from treatment[2].  
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a) 
 
b) 
 
 
 
Figure 3.5. a) Riboflavin concentration profile inside corneal tissue after 30 minutes of 
applying drug using the clinical dose of 0.1%. b) Keratocyte toxicity is observed in the 
anterior 300-350 µm of the corneal stroma after riboflavin/UVA treatment. (Image 
adopted from lasikcomplications.com)   
 
Unlike riboflavin/UVA treatment, collagen cross-linking activated by eosin Y using 
visible light has relatively low toxicity (Chapter 6). Therefore, the combination of eosin 
Y and visible light can be optimized for efficacy (Chapter 5). The low cytotoxicity of 
eosin Y and visible light may expand the range of patients who can safely receive corneal 
cross-linking treatment to include cases of advanced keratoconus or post-LASIK ectasia, 
in which corneal thickness is frequently less than 400 µm[13].  
 
3.5 CONCLUSION 
Photorheology can be used to efficiently characterize the effects of treatment parameters 
(including photosensitizer concentration and irradiation intensity) on the cross-linking 
rate of therapeutic collagen cross-linking. In the specific case of eosin Y activated by 
green light, photorheology indicates that the rate and extent of collagen cross-linking can 
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match those of riboflavin activated by UVA at the conditions that have proven to be 
clinically efficacious. The kinetic data provided by photorheology can be used in a 
predictive model of collagen cross-linking to anticipate the safety and efficacy of 
proposed treatment protocols (Chapter 5).    
 
3.6 APPENDIX 
 
a) 
  
b) 
 
Figure 3.6. Storage modulus as a function of time for 450 µm thick gel samples with a) 
eosin Y and b) riboflavin. Samples containing eosin Y were irradiated with green light at 
530 ± 15 nm and those containing riboflavin were irradiated with UV light at 370 ± 15 
nm. The presence of both drug and light are necessary for enhancing the storage modulus. 
(To avoid over-crowding of the figures, only three samples are shown for each 
condition.) 
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Chapter 4 
Transcorneal and Transcleral Transport of Eosin Y and 
Riboflavin 
 
4.1 INTRODUCTION 
A 
Topical drug delivery is the dominant route for ocular drug delivery due to the 
accessibility of the front of the eye, the minimal risk of infection, and the ability to 
transfer drug into the ocular coat (cornea and sclera), anterior chamber and its associated 
tissues[1-4]. To reach any of these tissues, topically applied drug must penetrate the ocular 
coat; therefore, it is important to understand the transport across these tissues. Here, we 
focus on the transport of drugs through the ocular coat with specific interest in treating 
diseases associated with progressive thinning and weakening of the ocular coat, including 
keratoconus, post-LASIK ectasia and degenerative myopia. Photo-activated cross-linking 
treatments have been proposed for halting the progression of these diseases by 
strengthening the weakened tissue[5-10]. The safety and efficacy of cross-linking 
treatments depend on the local drug concentration and light intensity as a function of 
depth into the tissue. This study aims to characterize the transport of both riboflavin, 
which is currently being used clinically, and eosin Y, which is a less toxic photosensitizer 
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(Chapter 6). The development of less toxic routes to tissue cross-linking would enable 
treatment of patients with post-LASIK ectasia and degenerative myopia, in addition to 
keratoconus. 
Keratoconus is a bilateral corneal thinning disorder with a prevalence of 1 out of 
2,000[11]. This eye disease is characterized by progressive corneal thinning and 
protrusion[11-13]. Post-LASIK ectasia is a complication of refractive surgery that results in 
corneal thinning and protrusion, similar to keratoconus[14-16]. Post-LASIK ectasia has an 
incidence of 1 out of 2,500 LASIK surgical procedures[17]. Degenerative myopia is 
associated with the progressive thinning and stretching of the posterior sclera[18, 19]. It is 
the leading cause of blindness in Asia and is ranked 7th in the United States[20].  
Therapeutic cross-linking using riboflavin activated by UVA irradiation pioneered by 
Wollensak, Spoerl, and Sieler has been shown to be promising for halting the progression 
of keratoconus[6, 21]. Riboflavin/UVA treatment has not yet been successfully 
demonstrated in treating corneal ectasia for patients with cornea thinner than 400  
μm[6, 22, 23] or degenerative myopia[10, 24]. Motivated by the need for a safer cross-linking 
treatment, we have investigated eosin Y, a visible light activated photosensitizer that has 
been approved by the FDA for use in the body[25]. 
Even though riboflavin/UVA treatment has been performed on keratoconus patients for 
almost a decade[26], the transport of riboflavin into the corneal stroma has not yet been 
quantified. Although two studies examine the concentration profile of riboflavin as a 
function of depth in the cornea, Sondergaard et al.[27] using confocal fluorescence 
microscopy and Cui et al.[28] using two-photon excited fluorescence technique, the 
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reported maximum concentration of riboflavin in the tissue differs by two orders of 
magnitude. There is also a discrepancy in the reported shapes of the concentration 
distribution of riboflavin along the tissue depth.  
Fundamentally, knowledge of the diffusion and partition coefficient of the molecule in 
the tissue is needed to predict the time evolution of the amount and distribution of drug 
transferred into the tissue. We were unable to find any literature on the diffusion and 
partition coefficient of riboflavin in the cornea or sclera. Riboflavin has a similar 
molecular structure and molecular weight to fluorescein, a compound used extensively in 
ophthalmology, so its diffusion and partition coefficient has been measured in various 
studies[29-31]. A theoretical concentration profile of riboflavin in the cornea has been 
predicted before using fluorescein’s diffusion coefficient (D = 65 µm2/s) and assuming a 
partition coefficient of 1[32].  
Transport through the ocular coat tissues has been commonly studied using an Ussing 
chamber to determine the permeability of the compounds of interest across the cornea or 
sclera[33-35]. Permeability is the product of the partition coefficient and diffusivity divided 
by the tissue thickness[36]. Other techniques have been developed to determine the 
partition coefficient and diffusivity. One technique involves applying drug to the end of a 
strip of cornea or sclera and monitoring the concentration at various positions along the 
strip as a function of time either by measuring the tissue fluorescence or sectioning the 
tissue and performing extraction. The concentration profile was fit to a 1-dimensional 
diffusion model[30, 31, 37, 38] to determine the partition and diffusion coefficient. Another 
technique entails immersing a cross-section of the sclera in a solution to saturate the 
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tissue, then transferring the cross-section into a solute-free solution and measures the rate 
of solute leaving the cross-section and then fitting the data to a diffusion model to 
determine the diffusion coefficient[37].  
Our study examined the transport of molecules into an intact globe, which mimics in vivo 
conditions and avoids damaging the tissue structure from cutting. After drug was 
delivered to the eye, the cornea or sclera was isolated to extract the molecules delivered 
to the tissue as a function of contact time with the drug solution. We then applied a 
diffusion model to fit the data. From this, we were able to determine the partition 
coefficient, k and diffusion coefficient, D. Absorbance measurements of the tissue cross-
sections were performed to check for consistency with the extraction measurements. The 
absorbance method for quantifying the amount of drug delivered was also used to 
compare different delivery techniques (drops and different formulations of viscous gels) 
to determine which would be worthy of pre-clinical evaluation.  
4.2 METHODS 
Drug diffusion into the cornea – Sierra for Medical Science supplied porcine eyes from 
3-4 month old swine. Eyes were stored in ocular balanced saline solution on ice until use 
within 48 hours post mortem. Corneal tissues were all clear with no signs of edema. The 
epithelial cell layer was removed by scraping with a scalpel. Each eye was immersed in 
30 mL of drug solution, either 0.289 mM (0.02%) eosin Y (Sigma Aldrich E6003) 
solution in Dulbecco’s phosphate buffered saline (DPBS, Sigma D8662) or 0.289 mM 
(0.0138%) riboflavin 5’-monophosphate sodium salt (riboflavin, Fluka 77623) solution in 
DPBS. The drug solution containing the eye was gently agitated using a rocker for a 
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specified “drug contact time” (tc,cornea ranging from 0 to 4 hours). After the drug contact 
time, the eye was removed from the drug solution, and excess solution on the cornea was 
dabbed away with a Kimwipe (Figure 4.1a). The eye was dissected using a scalpel blade 
and a pair of scissors to cut around the corneoscleral limbus to separate out the cornea 
(Figure 4.1b). The tissue section was placed onto a trephine punch to cut out a 9.5-mm 
diameter corneal cross-section (Figure 1c). The sizes of the cross-sections were very 
consistent with mass of 95 ± 12 mg for eyes with tc,cornea = 0 hr. 
 
a) 
 
b) 
 
 
      
c) 
 
 
            
Figure 4.1. a) Eye removed from eosin Y solution when contact time completed. b) 
Dissection to separate the cornea. c) Trephine punch used to cut out a 9.5-mm diameter 
cross-section of the cornea.  
 
Drug diffusion into the sclera – Orbital tissues were removed with scissors to expose the 
sclera. Each eye was placed into 30 mL of a drug solution (either Eosin Y or riboflavin) 
and gently agitated using a rocker for a specified contact time (tc,sclera ranging from 0 to 
120 hours). After the contact time, the eye was removed from the drug solution, and 
excess solution on the sclera was dabbed away with a Kimwipe. The eye was dissected 
using a scalpel blade and a pair of scissors to obtain a posterior scleral section on the 
temporal side near the optic nerve (Figure 4.2b). The tissue section was placed onto a 
trephine punch to cut out a 9.5-mm diameter cross-section (Figure 4.2c). 
Dissect 
Trephine 
punch 
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a) 
          
b) 
 
 
     
c) 
 
 
 
            
Figure 4.2. a) Eye removed from eosin Y solution when contact time completed. b) 
Dissection to separate the sclera section near the optic nerve. c) Trephine punch used to 
cut out a 9.5-mm diameter cross-section of the sclera.  
 
Quantitative assay of the amount of drug delivered – Experiments were performed for 
five drug contact times (four samples each): for the cornea, tc,cornea = 0.25, 0.5, 1, 2, and 4 
hrs, and for the sclera, tc,sclera = 0.5, 2, 4, 7.5, and 120 hrs. Each experiment was repeated 
four times. For each experiment, the 9.5-mm diameter tissue cross-section obtained as 
described above was placed into a 50 mL centrifuge tube and immersed in 50 mL of 
extractant (doubled-distilled water for cornea or DPBS for sclera) then placed on a rocker 
to extract the drug molecules (Figure 4.3). DPBS was used instead of water to extract 
drug from the sclera because eosin Y did not partition favorably from the sclera into 
water. After a first extraction time te,1 of 8 hours, the tissue specimen was then 
transferred into another 50 mL of fresh extractant and the extract was retained for 
analysis.  
The concentration of the drug in the extract was determined using fluorimetry. Eosin Y 
was excited at 514 nm and the fluorescence was detected at 534 nm; for riboflavin, the 
excitation wavelength was 466 nm and detection wavelength was 523 nm. The 
fluorescence of each extract was measured and concentration was determined based on 
calibration curves prepared for each compound using a series of solutions with known 
Dissect 
Trephine 
punch 
IV-7 
 
concentrations. The extraction process was repeated using successively longer extraction 
times until there was no detectable fluorescence in the supernatant. For the cornea, three 
extractions were sufficient, with te,1 = 8, te,2 = 24 and te,3 = 48 hours (a total extraction 
time of 48 hours). For the sclera, five extractions were required with te,1 = 8, te,2 = 24,  
te,3 = 48, te,4 = 72, te,5 = 96, and te,6 = 120 hours (a total extraction time of 120 hours). The 
final extraction time was only needed for sclera specimens that had been kept in contact 
with eosin Y for tc,sclera = 120 hours. 
 
 
 
 
          
 
    
Figure4. 3. Quantitative assay of the amount of molecules transferred to the tissue cross-
section. The section was placed into 50 mL of double-distilled water for 8 hours, then 
transferred to a new 50 mL of double-distilled after 24 hours, then transferred again after 
48 hours. 
 
Assessing residual eosin Y remaining in tissue after extraction – Eosin Y is known to 
bind to collagen[39, 40] which makes up more than 68% of the cornea’s dry mass[36] and 
more than 80% of the sclera’s dry mass[36]. Therefore, light absorption measurements 
were performed to exclude the possibility that a significant amount of eosin Y remained 
in the tissue after extraction. One cornea specimen was prepared as above for each of the 
following drug contact times: tc,cornea = 0.25, 1, and 4 hrs. Before placing the corneal 
cross-section into the first extractant, its UV-vis absorption spectrum was measured. 
There was a distinct peak at 525 nm with absorbance value greater than 2 for all samples 
Transfer  Transfer  
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(i.e., transmitted intensity was < 0.01 of the incident intensity). Eosin Y was then 
extracted from the corneal cross-sections into double distilled water using three 
successive extractions with te,1 = 8, te,2 = 24 and te,3 = 48 hrs as described above. After the 
last extraction, UV-vis absorption spectrum of the corneal cross-section was measured 
again. Even though the corneas were cloudy after the extraction process, the absorbance 
values were ~1.2 (i.e. transmitted intensity was ~5% of the incident intensity), and the 
peak at 525 nm was no longer present in any of the three cornea specimen.  This 
demonstrates the amount of eosin Y remaining in the tissue specimen after the extraction 
procedure is negligible compared to the amount extracted. Riboflavin does not bind to 
collagen; therefore, none is expected to remain in the tissue after extract is complete.  
Absorbance measurement to determine the amount of drug delivered – The extraction 
method provides a quantitative measure of the number of drug molecules delivered; 
however, the procedure requires 48 hours to 120 hours. For determining the number of 
molecules transferred to the cornea as a function of the delivery protocol and delivery 
vehicle, light absorption measurements suffice to characterize the number of drug 
molecules delivered to the cornea. Once the drug delivery step is complete, a 9.5-mm 
diameter cross-section of the central cornea was obtained as described above (Figure 4.4). 
After taking a “blank” absorbance reading with the empty cuvette, the corneal section is 
placed into the cuvette and the sample’s absorbance was measured at the wavelength of 
the maximum absorbance of the drug (e.g., at 525 nm for eosin Y) in the tissue. Using the 
calibration curves described above, the amount of drug delivered was calculated from the 
absorbance of the corneal section.   
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a) 
 
b) 
 
 
   
c) 
 
 
         
d)   
        
Figure 4.4. a) Eye removed from eosin Y solution when contact time completed. b) 
Dissection to separate the cornea. c) Trephine punch used to cut out a 9.5-mm diameter 
cross-section of the cornea. d) The section was placed into a cuvette to measure the 
absorbance. 
 
Number of molecules delivered to each cornea was calculated from the absorbance using 
the following equations 
 𝐴𝑜 =  𝜀𝑜 ∙ 𝐿 Equation 1 
where Ao is the apparent absorbance of the control sample soaked in DPBS for 5 minutes, 
ɛo is the extinction coefficient of the cornea, and L is the thickness of the sample.  
 𝐴 =  𝜀𝑜 ∙ 𝐿 + 𝜀𝐸𝑌 ∙ 𝐶 ∙ 𝐿 Equation 2 
where A is the absorbance of the sample with eosin Y and ɛEY is the extinction coefficient 
of eosin Y, C is the of eosin Y concentration inside the tissue. Subtracting Equation 1 
from Equation 2 and rearranging yields 
 
𝐶 ∙ 𝐿 =  𝐴 − 𝐴𝑜 
𝜀𝐸𝑌
 Equation 3 
The product of concentration and sample thickness is the number of drug molecules 
delivered per unit area. 
Dissect 
Trephine 
punch 
Measure 
absorbance 
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This method was used to compare different drug delivery techniques in vitro to determine 
which would be worthy of preclinical evaluation in vivo: 1) immersion in drug solution, 
2) topical drops of drug solution, and 3) topical application of a gel. These three drug 
delivery techniques were examined using porcine eyes from 3-4 month old swine (Sierra 
for Medical Science) stored in saline on ice until use within 48 hours post mortem. The 
epithelial cell layer was removed from the cornea by scraping with a scalpel. Drug was 
delivered to the cornea using one of the following techniques (or the corresponding 
control): 
1) Immersion: Each eye was immersed in 30 mL of 0.289 mM (0.02%) eosin Y solution 
that was gently agitated using a rocker. After 5 minutes, the eye was removed from the 
eosin Y solution, and excess solution on the cornea was dabbed away with a Kimwipe. 
Control eyes were placed in 30 mL of DPBS solution instead of eosin Y solution. 
2) Topical drops: Drops of 0.289 mM eosin Y in DPBS solution were applied to the 
cornea every minute for 5 minutes. Excess solution on the cornea was dabbed away with 
a Kimwipe. 
3) Topical gel: Four different viscosity enhancers were examined, each at a concentration 
such that the gel would remain on the cornea for 5 minutes: 2% hyaluronic acid (HA), 
3% carboxymethylcellulose (CMC), 3% sodium alginate (SA), and 3% methylcellulose 
(MC) each in DPBS. Approximately 0.5 mL of 0.289 mM eosin Y gel was applied to the 
cornea using a syringe and then the gel was spread evenly over the cornea and limbus 
using a spatula. Hyaluronic acid provided a gel that was free of bubbles, but it was 
somewhat difficult to spread into an even layer. Sodium alginate and methylcellulose gels 
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were easy to spread, but retained air bubbles. Carboxymethylcellulose provided a gel free 
of bubbles that spread easily with a spatula. After 5 minutes, the gel was removed from 
the cornea with a spatula and the site was quickly rinsed with ~2 mL of DPBS. Excess 
solution was then dabbed away with a Kimwipe 
4.3 RESULTS 
Cornea samples required two extracts to remove the delivered drug molecules  
(Figure 4.5). For all contact times examined (0.25, 1, 2, and 4 hours), the second extract 
contained much less drug than the first (for eosin Y, 3 to 6% and for riboflavin, 1.6 to 
2.5% of the first extract) and the third extract had negligible drug (fluorescence value was 
similar to that of doubled-distilled water, indicating a drug concentration less than 1% of 
the first extract). Therefore, we approximate the total number of drug molecules delivered 
to the cornea during tc as the sum of the number of drug molecules in the three extracts 
(Figure 4.6a). 
Sclera samples required more extractions than cornea samples, particularly for eosin Y. 
For all contact times examined (0.5, 2, 4, 7.5, 30, and 120 hours), the amount of eosin Y 
in the second extract was a substantial fraction of that in the first extract, between 10 to 
45% (e.g., for 2 hours contact time, the second extract contained approximately 20% as 
much as the first extract, Figure 4.5b). As the duration of the extraction step increased, 
the ratio of the content of eosin Y in the successive extracts approached a constant value 
of approximately 1/3; specifically, relative to the first extract, the amount of eosin Y in 
the subsequent extracts was between 3 to 22% in the 3rd, between 2 to 8% in the 4th, 
between 0-2% in the 5th and ≤ 1% in the 6th. Riboflavin was much more readily extracted 
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from the sclera: relative to the first extract, the second extract contained only 3 to 6%, the 
3rd extract contained between 1 to 3%, and the 4th extract ≤ 1%. Therefore, we also 
approximate the total number of drug molecules delivered to the sclera during tc as the 
sum of the number of drug molecules in all the extracts (Figure 4.6b). 
 
  a) 
  
  b) 
 
Figure 4.5. Number of drug molecules, eosin Y and riboflavin, in successive extracts 
from tissue specimens given a 2 hours contact time for the a) cornea and b) sclera. 
Approximately all of the extractable molecules were removed from the cornea after 3 
extractions, and from the sclera after 5 extractions. Therefore, the sum of the number of 
drug molecules in all the extracts is a good approximation of all the drug molecules that 
had been transferred into the tissue cross-section. (N = 4) 
 
The total drug delivered per unit area of contact, estimated as the sum of the number of 
drug molecules in all extracts, normalized by the cross-sectional area of the sample, 
increases with drug contact time (Figure 4.6). The value levels off at long time as the 
system approaches equilibrium partitioning of drug between the tissue and the solution. 
For the cornea, the initial increase with drug contact time levels off at 2 hours for both 
eosin Y and riboflavin, indicating that the two molecules have similar diffusivities in the 
cornea; the long time asymptotes show that the eosin Y partitions more favorably into the 
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cornea than riboflavin does, by approximately a factor of 2 (Figure 4.6a). For the sclera, 
much longer time was required for the concentration to level off (note different time 
scales for part a and b of Figure 4.6).  Furthermore, the time scales were not the same for 
the two drugs (approximately 30 hours for eosin Y and approximately 7.5 hours for 
riboflavin); the sclera also showed a more dramatic difference in affinity for eosin Y and 
riboflavin – approximately 7-fold greater for eosin Y than riboflavin at the long time 
asymptotes (Figure 4.6b).  
 
  a) 
 
 b)  
 
Figure 4.6. Total number of drug molecules delivered as a function of drug contact time 
for both eosin Y and riboflavin in a) the cornea and b) the sclera. Note: all data points 
have associated error bars, however some error bars are too small to visible on the graph. 
(N = 4) 
 
The equilibrium partitioning of riboflavin between the drug solution and the tissue was 
quite similar for the cornea and the sclera. There is a pronounced difference in the 
equilibrium partitioning of eosin Y for the cornea and sclera with the sclera being much 
more favorable than the corneal stroma. Despite the much greater affinity of the sclera for 
eosin Y, the rapid rate of transport into the cornea led to greater eosin Y uptake by the 
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cornea than the sclera at short contact times (0.5 and 2 hours). The situation reversed at 
long contact times (4 hours in the cornea and 120 hours in the sclera), when significantly 
more eosin Y was absorbed by the sclera than the cornea. In contrast, approximately the 
same amount of riboflavin was absorbed by both of these tissues at long contact times. 
Evaluation of Partition Coefficients and Diffusion Coefficients  
A quantitative description of the number of drug molecules delivered to targeted tissue is 
crucial in the drug delivery aspect of developing safe and effective therapeutics. In 
addition to the quantity of drug delivered, photo-activated therapy is sensitive to the 
distribution of drug inside the tissues. Following Maurice[29], Nagataki et al.[30, 31], 
Prausnitz et al.[38, 41] we find that a simplified diffusion model provides a good 
description of the experiment results (see below) and, therefore, we it use to evaluate the 
partition and diffusion coefficients. The observed accord between the model and the 
present experimental results also indicates that the model can be used to predict the drug 
concentration profile inside the tissue as a function of treatment parameters (i.e. drug 
concentration, drug contact time, and the delay time from the drug application to drug 
activation via irradiation, which is discussed in Chapter 5).  
Porcine eyes closely resemble a sphere with diameter ~25 mm. The cornea and sclera are 
the targeted tissues and both have thicknesses that are on the order of 1 mm. Since these 
tissue thicknesses are less than a tenth of the diameter of the eye, they are modeled as 
semi-infinite slabs. Each tissue is approximated as a uniform material. Fick’s diffusion 
equation is given by 
IV-15 
 
 𝜕𝐶(𝑧)
𝜕𝑡
= 𝐷 𝜕2𝐶(𝑧)
𝜕𝑧2
 Equation 4 
where C(z,t) is the drug concentration inside the tissue, I is the time since the exterior 
surface of the tissue was placed in contact with the drug solution, z is the distance into the 
tissue from its exterior surface, and D is the diffusion coefficient. An initial condition and 
two boundary conditions are needed: the initial condition has no drug in the tissue, the 
concentration just inside the tissue (at z = 0) is given by the product of the partition 
coefficient and the concentration of the drug in the solution, and the concentration falls to 
zero far from the surface of the tissue. For short contact times, the concentration falls to 
zero before the profile reaches the endothelium. For longer contact times, the boundary 
condition that the concentration falls to zero far into the system is still used as a first 
approximation (neglecting the change in material properties at the endothelium and 
neglects different transport processes in the aqueous or vitreous).   
 Initial condition at 𝑡 = 0, 𝐶 =  0 for all 𝑧 ≥ 0 
Boundary condition at 𝑧 = 0, 𝐶 =  𝑘 ∙ 𝐶𝑑𝑟𝑢𝑔 for 𝑡 > 0 
Boundary condition at 𝑧 = ∞, 𝐶 =  0 for all 𝑡 
Equation 5.1 
Equation 5.2 
Equation 5.3 
where k is the partition coefficient and Cdrug is the concentration of the drug solution 
applied. Applying the initial and boundary conditions to the diffusion equation, the 
concentration profile is given by 
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  𝐶(𝑡, 𝑧) =  𝑘 ∙ 𝐶𝑑𝑟𝑢𝑔 ∙ 𝑒𝑟𝑓𝑐 � 𝑧
√4𝐷𝑡� Equation 6 
where erfc is the complementary error function. Using this theoretical concentration 
profile, the total number of drug molecules present in the tissue can be calculated by 
integrating over the thickness of interest 
  𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝑎𝑟𝑒𝑎
= �  𝑘 ∙ 𝐶𝑑𝑟𝑢𝑔 ∙ 𝑒𝑟𝑓𝑐 � 𝑧
√4𝐷𝑡�𝐿0 ∙ 𝑑𝑧 Equation 7 
where area represents the cross-sectional area of the tissue sample and L is the thickness 
of the tissue sample. At long drug contact time, the predicted concentration changes very 
slowly and approaches a value governed by the partition coefficient. At short drug 
contact times, the rate of change is strong and largely determined by the diffusivity. The 
measured number of molecules delivered per area is compared to the model to deduce the 
values k and D that minimize the mean-square deviation, S, between the predicted and 
observed values for a given drug-tissue pair: 
 
𝑆 =  ��� 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝑎𝑟𝑒𝑎
�
𝑖
− �
 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝑎𝑟𝑒𝑎
�
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑,𝑖�
2𝑁
𝑖=1
 Equation 8 
with i being the individual data point and N being the total data points used for the fit. 
Data fitting was performed by writing a program in MATLAB software. The quality of 
fit provided by the resulting values of k and D (Table 4.1) is good (all predicted values 
are within 15% of the average measured values), suggesting that the approximations 
made are acceptable (Figure 4.7).      
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Table 4.1. Values of diffusivity, D and partition coefficient, k for 
eosin Y and riboflavin penetrating into the cornea and sclera from 
DPBS. 
 D (µm2/s) k 
Cornea 
Eosin Y 62 ± 22 4.3 ± 0.7 
Riboflavin 79 ± 22 1.7 ± 0.2 
Sclera 
Eosin Y 6.2 ± 1.7 13.0 ± 1.1 
Riboflavin 27 ± 8.4 1.5 ± 0.6 
             
  a)   
   
  b) 
  
Figure 4.7. Total number of drug molecules delivered as a function of drug contact time 
for both eosin Y and riboflavin in a) the cornea and b) the sclera. The “best fit” curves 
were generated using a diffusion model with values of k and D given in Table 4.1. 
  
For the cornea, eosin Y’s partition coefficient is greater than that of riboflavin  
(kc,EY  = 4.3, kc,R = 1.7), in accord with the difference noted above in their concentrations 
observed at long time. Eosin Y’s diffusion coefficient in the corneal stroma is similar to 
that of riboflavin (Dc,EY  = 62 µm2/s, Dc,R = 79 µm2/s), in accord with the similar time 
course for sorption noted above.  
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In contrast to the cornea, the difference in behavior between the two drugs is pronounced 
in the sclera. The partition coefficient for eosin Y is almost ten-times greater than that of 
riboflavin (ks,EY  = 13, ks,R  = 1.5), consistent with the much greater concentration of eosin 
Y than riboflavin at long times. The diffusion coefficient of eosin Y in the sclera is much 
less than that of riboflavin (Ds,EY  = 6.2 µm2/s, Ds,R  = 27 µm2/s), consistent with the much 
longer time required for eosin Y to reach its long-time asymptotic concentration than 
riboflavin.  
Comparing eosin Y’s behavior in the cornea and sclera shows its diffusivity is 
significantly greater in the cornea than in the sclera (Dc,EY  = 62, Ds,EY  = 6.2) and that it 
partitions into the cornea significantly less favorably than the sclera (kc,EY  = 4.3, 
 ks,EY  = 13.0). In contrast to eosin Y, riboflavin’s diffusion coefficient in the cornea is 
only three-times greater in sclera (Dc,R  = 79 µm2/s, Ds,R  = 27 µm2/s), and its partition 
coefficient is almost the same in the two tissues (kc,R  = 1.7, ks,R = 1.5). 
The extraction method and absorbance method for quantifying drug delivery were 
compared using three different delivery techniques: soak, drops, and 2% hyaluronic acid 
gel for 5 minutes (as described earlier). The two methods gave consistent results  
(Figure 4.8a), validating the absorption measurement as a tool to study drug delivery.  
To facilitate controlled application of the drug formulation on the cornea, it is of interest 
to increase the viscosity of the solution. Here we compare four clinically relevant options: 
2% hyaluronic acid (HA), 3% carboxymethylcellulose (CMC), 3% sodium alginate (SA), 
and 3% methylcellulose (MC). Three out of the four types of gel (hyaluronic acid, 
carboxymethylcellulose, sodium alginate) delivered approximately the same amount as 
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topical drops (Figure 4.8b). Although methylcellulose gel delivered less than half as 
much drug as the other formulations, this may simply be due to the difficulty of removing 
air bubbles from the resulting gel.  
 
  a)  
   
 b)  
 
Figure 4.8. a) The extraction and the absorbance methods yield similar results for the 
number of molecules delivered to the cornea for three selected delivery techniques 
applied for 5 minutes. b) Comparison of different delivery vehicles using the absorbance 
measurement to determine the quantity of drug delivered in 5 minutes from gels using 
four different viscosity enhancing agents. (N = 4) 
 
4.4 DISCUSSION 
The values of the partition coefficient and diffusion coefficient enable prediction of the 
amount of drug transferred to the tissue and the distribution of drug in the tissue, which 
are very important to safety and efficacy in therapeutics. Corneal and scleral transport has 
been predominantly studied using an Ussing Chamber to measure the permeability of 
molecules through these two tissues. Permeability describes the rate of transport at steady 
state, which is not sufficient to predict the transient transport of drug from a topically 
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applied vehicle into the tissue. The permeability, P, is equal to the product of the partition 
coefficient and diffusion coefficient divide by the tissue thickness[36]. 
 
 
𝑃 =  𝑘𝐷
𝐿
 Equation 9 
Permeability measurements through the corneal stroma have mostly been studied in 
rabbit corneas[42]. For molecules with similar sizes (4.0 to 5.1 Å), reported permeability 
through rabbit stroma for 15 compounds range from 0.30 to 0.58 µm/s[42]. Permeability is 
inversely proportional to thickness, and after taking into account porcine stromas are 2.5 
times thicker than rabbit stromas[43, 44], the permeability values expected for the porcine 
cornea range from 0.13 to 0.25 µm/s, for molecules of comparable size to eosin Y and 
riboflavin. These values accord well with the values of permeability calculated using the 
diffusivity and partition coefficient for porcine cornea determined in this study, which are 
0.16 and 0.31 µm/s for riboflavin and eosin Y, respectively.    
Using the values of the partition coefficient and diffusivity for porcine sclera determined 
in this study, the calculated permeability is 0.050 µm/s for riboflavin and 0.099 µm/s for 
eosin Y. For molecules of similar sizes (3.3 to 4.9 Å), reported permeability through 
rabbit sclera is 0.25 to 0.71 µm/s for 4 compounds, human sclera is 0.15 to 0.44 µm/s for 
6 compounds, and bovine sclera is 0.065 to 0.13 µm/s for 2 compounds[42]. When scaled 
for tissue thicknesses[45], the range of permeability values expected for porcine sclera is 
0.050 to 0.14 µm/s (based on rabbit data), 0.060 to 0.18 µm/s (based on human data), 
0.042 to 0.084 µm/s (based on bovine data). Thus, the literature values for scleral 
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permeability are consistent with the partition coefficient and diffusion values obtained in 
this study. 
The observed values of the partition coefficients for the two drugs into the cornea and 
sclera provide interesting information on the interaction between the drugs and the 
constituents of the tissue. While a molecule’s lipophilicity and charge are also expected 
to affect the partition coefficient[36], that cannot explain the significantly greater partition 
coefficients of eosin Y relative to riboflavin (Table 4.1): both compounds readily dissolve 
in water and both are negatively charged in solution at physiological pH[40, 46, 47]. The 
partition coefficient also depends on the binding interactions between the drug molecules 
and the tissue[38, 41]. 
A partition coefficient greater than one is indicative of an attractive interaction, between 
the drug and one or more constituents of the tissue. In the case of the corneal stroma and 
the sclera, the main constituents are collagen fibrils embedded in a matrix of 
proteoglycans and water. For hydrated corneal stromas (as in the present experiments), 
the estimated volume fraction of water is 89.7%, while that of collagen is  7.3% and the 
remaining 3% consists of proteoglycans, non-collagenous free proteins and salts[36]. The 
sclera has substantially greater collagen content and correspondingly lower water content: 
the estimated volume fraction of water is 77.7% and that of collagen is 18.4% (like the 
cornea, the remaining 3.9% v/v of the sclera consists of proteoglycans, non-collagenous 
free proteins and salts[36].  
Riboflavin exhibits partition coefficients that are only mildly greater than one and are 
similar for the cornea (kc,R  = 1.7 ± 0.2) and sclera (ks,R = 1.5 ± 0.6). These results indicate 
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that riboflavin does not have a strong affinity for collagen or proteoglycans. In contrast, 
eosin Y exhibits partition coefficients that are substantially greater than one and are 
substantially different in the cornea (kc,EY  = 4.3 ± 0.7) and sclera (ks,EY = 13.0 ± 1.1). 
Eosin Y is known to bind to various proteins, including collagen[39, 40]. Eosin Y’s 
partition coefficient in the sclera is 3 times that in the cornea, which correlates with the 
volume fraction of collagen present in these tissues (2.5 times greater in the sclera). 
Another molecule that is known to bind to collagen is sulforhodamine[48-50]. Its partition 
coefficient in the sclera is 13.6[38] similar to that of eosin Y.  
Accurate values of the partition coefficient are important in understanding the transport 
of drug into the tissue. During transient introduction of a given drug to the tissue from a 
topically applied vehicle, the concentration profile as a function of depth into the tissue at 
a particular contact time is directly proportional to the partition coefficient (Equation 6). 
In prior literature on corneal collagen cross-linking with riboflavin, the concentration 
profile in the tissue has been estimated assuming a partition coefficient of 1[32], which 
under-estimates the riboflavin concentration. Based on the value determined in porcine 
tissue in vitro (ks,R  = 1.7 ± 0.2), and the similarity between porcine and human cornea[51], 
we expect the actual concentration to be 70% greater than estimated using k = 1. This 
represents a significant error with respect to understanding the toxicity observed for 
riboflavin combined with UV irradiation.  
While, the partition coefficient determines the concentration immediately inside the 
tissue relative to that in topically applied vehicle, the diffusion coefficient determines 
how rapidly molecules are transported into the tissue. Diffusion of drugs in the stroma 
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and sclera has been modeled by considering the tissue as a composite consisting of 
impermeable collagen fibrils embedded in a gel matrix of proteoglycan and water[36]. A 
molecule’s diffusion rate through the stroma and sclera depends on its binding interaction 
with the tissue, the volume fraction of the impermeable collagen fibrils, and its molecular 
size[36].  
The greater the affinity of the drug for the proteins or proteoglycans in the tissue, the 
lower the effective diffusion coefficient is. A one-dimensional diffusion model with 
binding interactions developed by Jiang et al.[38] accounts for the binding effect 
separately from the diffusion process. The effective diffusion coefficient, D, is modeled 
as the product of the “free” diffusivity (without binding), Dab, and the fraction of 
molecules that are in the “free” state:  
 
𝐷 =  𝐷𝑎𝑏 𝐾𝑒𝑞 1 + 𝐾𝑒𝑞 Equation 10 
where Keq is the ratio of free-to-bound molecules in the tissue at equilibrium, 
 
𝐾𝑒𝑞 =  𝐶𝑓𝑟𝑒𝑒 𝐶𝑏𝑜𝑢𝑛𝑑 Equation 11 
 The model eliminates Keq in favor of the partition coefficient, which can be viewed as  
 
𝑘 =  𝐶𝑡𝑖𝑠𝑠𝑢𝑒 
𝐶𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
= 𝐶𝑓𝑟𝑒𝑒 + 𝐶𝑏𝑜𝑢𝑛𝑑  
𝐶𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
 Equation 12 
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where Csolution is the concentration of the compound in the bath solution in contact with 
the tissue, which is assumed to be equal to the concentration of “free” molecules in the 
tissue. This yields 
 
𝑘 = 1 +  1 
𝐾𝑒𝑞
 Equation 13 
Combining Equation 13 and 10, we can evaluate Dab from our results for each pair of k 
and D 
 𝐷𝑎𝑏 = 𝑘𝐷 Equation 14 
 
Table 4.2. Deduced values for the “Free” diffusivity, Dab 
from the observed effective diffusitivity, D and the partition 
coefficient, k, for eosin Y and riboflavin in the cornea and 
sclera. 
 D (µm2/s) k Dab (µm2/s) 
Cornea 
Eosin Y 62 4.3 267 
Riboflavin 79 1.7 134 
Sclera 
Eosin Y 6.2 13.0 81 
Riboflavin 27 1.5 41 
    
In view of the model, the free diffusivity for riboflavin and eosin Y can be evaluated 
from each pair of k and D (Table 4.2). For each drug, its free diffusivity Dab in the cornea 
is three times greater than in the sclera. Molecules diffusing through these tissues must 
diffuse around the impermeable collagen fibrils so the more collagen the tissue has, the 
more tortuous the diffusion path is expected to be.  
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For a given tissue, Dab is proportional to permeability (Equation 9 and 12), which 
depends strongly on the molecular radius[42]. Therefore, it is interesting to note that the 
free diffusivity of riboflavin is half that of eosin Y. Riboflavin’s hydrodynamic radius is 
5.8 Å[52]. Although no reported value for eosin Y’s hydrodynamic radius was found, it is 
expected to be similar to fluorescein’s, which is 4.8 Å[42]. Based on the correlation 
between permeability of the corneal stroma and the hydrodynamic radius of the 
permeant[42], a decrease in hydrodynamic radius from 5.8 Å to 4.8 Å, is expected to 
increase stromal permeability by a factor of 1.7. Thus, the observed ratio of the free 
diffusivities of riboflavin and eosin Y can be understood in terms of their hydrodynamic 
radii.  
The effective diffusion coefficient determines how rapidly molecules penetrate through a 
given tissue, which controls the transient distribution of drug inside the tissue following 
application of a drug formulation on its surface. In a safety study of corneal collagen 
cross-linking with riboflavin, the drug concentration profile was calculated using 
fluorescein’s effective diffusion coefficient, D = 65 µm2/s[32]. This approximation is 
indeed close to riboflavin’s diffusivity (D = 79 µm2/s); consequently the error resulting 
from the approximated diffusivity is small (~10%) relative to the error resulting from the 
approximation used previously for the partition coefficient (~70%) described above. 
Selection of delivery vehicles for in vivo treatments of the cornea can be guided by 
quantitative comparison of the amount of drug transferred to the tissue. Soaking provides 
a benchmark (Figure 4.8a) that can be regarded as a best possible scenario (an infinite 
reservoir of drug in continuous contact with the tissue with some convective transport).  
IV-26 
 
There are many options that provide results that approach that of soaking (i.e., reduced by 
30-40% relative to soaking). Application of drops, approximately 3/4 as much drug 
transfer as soaking and is clinically feasible. Viscous gels provide approximately 2/3 as 
much drug transfer as soaking (Figure 4.8). The selected viscosity enhancers (hyaluronic 
acid[53, 54], carboxymethylcellulose[55, 56], sodium alginate[57], and methylcellulose[58] have 
been widely used in various ocular drug delivery systems. Among the different gels 
studied, carboxymethylcellulose (CMC) formulation was clear, smooth, free of air 
bubbles and the easiest to handle for spreading onto the cornea; therefore, CMC gel was 
selected as the delivery vehicle for in vitro and in vivo corneal treatment (Chapter 6).  
4.5 CONCLUSION 
Measurements of the amount of drug delivered to a target tissue (cornea or sclera) as a 
function of delivery time enable determination of the partition coefficient and diffusion 
coefficient of two drugs that are relevant to collagen cross-linking—riboflavin and eosin 
Y. The method can be extended to other drug molecules and to other tissues. The values 
of the diffusion coefficient and the partition coefficient provide essential information to 
predict the drug concentration profile in the tissue as a function of drug concentration, 
application time, and delay time between drug application and irradiation (Chapter 5). 
Knowledge regarding the drug concentration profile is critical to understanding the 
penetration of light into the tissue and, in turn, the spatial distribution of cross-link 
formation inside the tissue as a function of treatment conditions.   
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Chapter 5 
A Model for the Photodynamic Collagen Cross-linking 
Treatment 
 
 
5.1 INTRODUCTION 
Keratoconus is an ocular disease characterized by progressive corneal thinning, 
protrusion, and scarring, resulting in irregular astigmatism and myopia. It is a bilateral 
corneal ectasia with a prevalence of 1 out of 2,000, affecting people of all ethnicities and 
genders equally[1]. Cornea thinning appears to result from loss of material, but it is 
unclear how or what causes this to happen. Increases in collagenase and other protease 
activities have been cited as important in the development of corneal ulcerations and 
keratoconus[2-4]. The corneas of keratoconus eyes are found to have fewer collagen 
lamellae, fewer collagen fibrils per lamella, closer packing of collagen fibrils or various 
combinations of these factors resulting in a weakened structure. 
Wollensak et al. has developed a treatment for halting the progression of keratoconus by 
inducing corneal collagen cross-linking[5, 6]. The treatment uses riboflavin activated by 
UVA to form cross-links inside the cornea. Cross-links serve two important roles in the 
treatment: to enhance the tissue strength and to increase resistance to collagen 
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degradation by enzymes[2, 7, 8]. Riboflavin/UVA has shown an ability to halt the 
progression of keratoconus in patients for studies lasting up to 6 years[5, 6]. However, 
there are drawbacks to the treatment, including cytotoxicity in the cornea which leads to 
corneal haze for weeks to months following surgery, and it uses a lengthy surgical 
procedure (60 minutes per eye). Because the treatment is toxic to both keratocytes and 
endothelial cells, the treatment was carefully designed to limit cytotoxicity to the anterior 
350 μm[9-12]. A high drug concentration and long drug delivery time prior to cross-linking 
ensures that there is enough riboflavin in the tissue to block UV light from penetrating to 
the endothelium, and only patients with corneas thicker than 400 μm can be treated. Thus, 
there is a need for an improved cross-linking treatment to reduce toxicity and treatment 
time. Eosin Y/visible light can potentially provide such a treatment (Chapter 6).  
Since treatment efficacy depends on both the quantity and distribution of cross-links 
formed along the tissue depth, studies have examined various properties of the treated 
tissue at different depths (i.e. change in biomechanical strength[7], maximum 
hydrothermal shrinkage temperature[13], collagen fiber diameter[14], and hydration[15]). 
These comparisons were made using bulk sections of the tissues, so they do not provide 
information regarding the extent of cross-linking as a function of tissue depth. Here, we 
create a model to quantify the extent of cross-linking as a function of depth for collagen 
cross-linking induced by photosensitizers. This model provides a more detailed map of 
the spatial distribution of cross-links for the riboflavin/UVA treatment. It can also be 
used as an optimization tool for selecting treatment parameters for the eosin Y/visible 
light treatment. 
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Photodynamic collagen cross-linking treatment has many treatment parameters including 
drug concentration, drug contact time, delay time between the end of contact time to the 
beginning of irradiation period, and irradiation intensity and duration (Figure 5.1). Each 
parameter affects the safety and efficacy of the treatment and all of the combined 
parameters yield a very large treatment parameter space. With such a large treatment 
parameter space, it would be very laborious and costly to optimize the treatment by 
carrying out experiments. A model can provide insights of how each parameter and 
combinations of parameters affect the outcome of the treatment.     
5.2 METHODS 
Design of experiments – The collagen gel photorheological technique discussed in 
Chapter 3 was used to gather collagen cross-linking rate data in order to model the extent 
and distribution of cross-link formation in the tissue. Collagen gel samples have uniform 
drug concentration profiles based on the preparation technique developed in Chapter 3. 
The protocols for collagen gel preparation and photorheological measurement are 
described in the Methods Section of Chapter 3. The pairs of drug concentrations and 
collagen gel thicknesses were selected such that the intensity profile is approximately 
uniform throughout the sample. Based on light intensity calculations, this is achieved 
when the ratio of light penetration depth over sample thickness is 1.2. The light intensity 
profile in the sample is given by: 
 𝐼(𝑧) = 𝐼𝑜𝑒−(𝜇+𝐶𝜀)𝑧 Equation 1 
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where I is the intensity, Io is the incident intensity, z is the position inside the collagen gel 
sample, µ is the collagen gel’s absorptivity, C is the drug concentration, and ε is the 
drug’s molar absorptivity. Light enters the sample through a quartz window which is part 
of the lower plate geometry on the rheometer where the sample sits and travels through 
the sample to the upper tool made of aluminum. Some of the light hitting the upper tool 
gets reflected and some gets scattered. For simplicity, we approximate that all the light 
hitting the upper aluminum tool gets reflected and travels back down the sample and the 
profile of the reflected light is also given by Beer’s law. Therefore, the total intensity the 
sample is exposed to at a given position is the sum of the incident light plus the reflected 
light.  
 
 𝐼(𝑧) = 𝐼𝑜𝑒−(𝜇+𝐶𝜀)𝑧 + 𝐼𝑜𝑒−(𝜇+𝐶𝜀)𝐿𝑒−(𝜇+𝐶𝜀)(𝐿−𝑧) Equation 2 
 
 
Based on this light intensity calculation approach, pairs of drug concentration and sample 
thickness were selected such that the light intensity profile is approximately uniform 
throughout the sample. For 450 μm thick riboflavin samples, the light intensity profile is 
approximately uniform throughout for concentrations less than or equal to 0.03%. For a 
225 μm sample, the intensity profile is approximately uniform for concentrations less 
than or equal to 0.05%. The highest concentration was limited by the minimum thickness 
of collagen gel samples that could be loaded onto the rheometer. The thinnest collagen 
gel samples that could be prepared and handled to yield reproducible results were 225 μm 
thick which corresponds to a 0.05% riboflavin concentration. For 450 μm thick eosin Y 
samples, the light intensity profile is approximately uniform for concentrations less than 
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or equal to 0.01%. For 225 μm samples, the intensity profile is approximately uniform for 
concentrations less than or equal to 0.02%. Rate data at these thicknesses and 
concentrations were used to build a model for cross-linking inside the tissue with non-
uniform drug concentration and light intensity profiles. 
Design of the model – Photodynamic collagen cross-linking depends on both the local 
photosensitizer concentration and the light intensity which are functions of treatment 
parameters: drug concentration, contact time (duration the drug is in contact with the 
tissue), delay time (period between end of contact time and beginning of irradiation), and 
irradiation time (Figure 5.1). Since drug is applied topically to the cornea, the 
photosensitizer concentration varies along the tissue depth with time. The concentration 
profile can be calculated using Fick’s diffusion equation. The light intensity also varies 
along the tissue as determined by Beer’s law. The cross-linking profile is also expected to 
vary along the depth since the local cross-linking rate depends on the photosensitizer 
concentration and light intensity. In order to evaluate the instantaneous local cross-
linking rate, the cornea is divided in thin sections along the visual axis so that each 
section has an approximately uniform concentration and intensity profile. Within each 
section, the instantaneous cross-linking rate is obtained from collagen gel photorhelogy 
data (rate of change in storage modulus) of collagen samples with uniform concentration 
profiles and approximately uniform light intensity profiles. The local change in storage 
modulus after a given irradiation time is the sum of the instantaneous changes in modulus 
at each time step. 
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Figure 5.1. a) Topical application of the drug formulation onto the cornea. b) Remove 
drug from the cornea at the end of contact time. c) Irradiation after a delay time. 
 
 
Using the partition coefficient and diffusion coefficient (Chapter 4) of the system we can 
calculate the concentration profile as a function of time for a selected topically applied 
drug concentration, contact time (duration the drug is in contact with the tissue), delay 
time (period between end of contact time and beginning of irradiation), and irradiation 
time.  
The cornea is the targeted tissue and it has a thickness on the order of 1 mm. Since the 
tissue thickness is less than an order of magnitude compared to the diameter of the eye 
(~24 mm), it is modeled as a semi-infinite slab of uniform material in which molecules 
can diffuse. Fick’s diffusion equation is given by 
 
 𝜕𝐶(𝑧)
𝜕𝑡
= 𝐷 𝜕2𝐶(𝑧)
𝜕𝑧2
 Equation 3 
 
 
where C is the drug concentration inside the tissue, t is time, z is the position inside the 
tissue, and D is the diffusion coefficient. An initial condition and two boundary 
contact 
time 
delay  
time 
[Eosin Y] 
Io 
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conditions are necessary to solve the equation. During the contact time, the appropriate 
conditions are 
 Initial condition at 𝑡 = 0, 𝐶 =  0 for all 𝑧 ≥ 0 Equation 4.1 
 
 Boundary condition at 𝑧 = 0, 𝐶 =  𝑘 ∙ 𝐶𝑑𝑟𝑢𝑔 for 𝑡 > 0 Equation 4.2 
 
 Boundary condition at 𝑧 = ∞, 𝐶 =  0 for all 𝑡 during the contact time Equation 4.3 
 
 
where k is the partition coefficient and Cdrug is the bulk concentration of the drug solution 
applied. Initially before drug is applied to the tissue, the concentration is zero everywhere 
inside the tissue (Equation 4.1). After the drug is applied, the surface of the tissue where 
drug diffuses into is always in equilibrium with the drug solution (Equation 4.2). During 
the drug contact time, the concentration is zero far into the tissue (semi-infinite slab of 
material approximation, Equation 4.3). Applying the initial and boundary conditions to 
the diffusion equation, the concentration profile is given by 
 
  𝐶(𝑡, 𝑧) =  𝑘 ∙ 𝐶𝑑𝑟𝑢𝑔 ∙ 𝑒𝑟𝑓𝑐 � 𝑧
√4𝐷𝑡� Equation 5 
 
 
where erfc is the complementary error function. The concentration profile evolves after 
the drug solution is removed. The concentration profile after a delay time is also given by 
Fickian diffusion (Equation 1) but with a different set of initial and boundary conditions. 
The concentration profile at the end of the contact time (Equation 5) is the initial 
condition for computing the concentration profile during the delay time profile. We 
approximate the system with a no flux boundary condition at the anterior surface because 
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drops of balanced saline solution are applied just enough to prevent corneal dehydration 
during the delay time. Based on this procedure, a negligible quantity of drug would be 
removed through the anterior surface of the cornea. 
 
  𝑑𝐶
𝑑𝑧
⃒𝑧=0 ≈ 0 during the delay and irradiation time Equation 6 
 
 
The flux at the back of the cornea is given by  
 
  𝐽|𝑧=𝐿 = ℎ𝑚(𝐶|𝑧=𝐿 − 𝐶𝑎𝑐) Equation 7.1 
 
 
where hm is the mass transfer coefficient in the anterior chamber, Cac is the concentration 
in the aqueous chamber. A calculation is done to determine how significant the flux 
through the back of the cornea into the aqueous chamber is relative to the amount of drug 
present in the tissue by comparing the flux leaving the cornea to enter the aqueous 
chamber, Jout to the average flux of drug entering the cornea, Jin during the contact time. 
As a conservative approximation, we use the greatest flux which is when Cac is 0. 
   
 𝐽𝑜𝑢𝑡
𝐽𝑖𝑛
=  ℎ𝑚𝐶|𝑧=𝐿
𝐶𝑎𝑣𝑔𝐿/𝑡  Equation 7.2 
 
 
where Cavg is the average drug concentration in the cornea after a given drug contact 
time. Reported values of hm for fluorescein in the cornea range from 1.15 x 10-4 to 2.3 x 
10-4 cm/min[16]. Using the largest reported value for hm, for a 5 minute eosin Y contact 
time, Jout/Jin is 7.9 x 10-4, and for a 30 minutes contact time Jout/Jin is 0.0655. The ratio 
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Jout/Jin is much less than 1 so the flux of drug leaving the cornea to enter the anterior 
chamber is not significant therefore the no flux boundary condition is also applied at the 
posterior surface of the cornea. 
 
  𝐽|𝑧=𝐿 = −𝐷 𝑑𝐶𝑑𝑧 ⃒𝑧=𝐿 ≈ 0 Equation 7.3 
 
 
Apply the initial condition given by Equation 4.1 and the boundary conditions given by 
Equation 6 and 7.3 to Fick’s diffusion equation to solve for the concentration profile with 
some delay time after the drug contact time. Since the boundary conditions are imposed 
on surfaces of constant coordinates (z = 0 and z = L), and the conditions are 
homogeneous, the equation can be solved using separation of variables 
 
 
𝐶(𝜏, 𝑧) =  �𝑎𝑛∞
1
𝑐𝑜𝑠 �𝑛𝜋
𝑧
𝐿
� 𝑒𝑥𝑝 �−
𝑛2𝜋2𝐷
𝐿2
𝜏� Equation 8.1 
 
   
where τ is the time since drug solution was removed from the corneal surface and an is 
 
 
𝑎𝑛 = ∫ 𝑘 ∙ 𝐶𝑑𝑟𝑢𝑔 ∙ 𝑒𝑟𝑓𝑐 � 𝑧√4𝐷𝑡� 𝑐𝑜𝑠 �𝑛𝜋 𝑧𝐿�𝐿0
∫ 𝑐𝑜𝑠2 �𝑛𝜋
𝑧
𝐿�
𝐿
0
𝑑𝑧 Equation 8.2 
 
 
Equation 8.1 and 8.2 give the concentration profile after the drug contact time, and 
throughout the irradiation time. This model does not take into account the consumption of 
the photosensitizer as the reaction occurs. This is an acceptable approximation since 
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collagen gel cross-linking experiments show a constant rate for ∆G' throughout a 30-
minute reaction period (Chapter 3). This implies the fraction of eosin Y consumption is 
negligible over this time period; therefore, as long as the irradiation period for the 
treatment is 30 minutes or less, this approximation is reasonable.  
For each concentration profile, the corresponding light intensity profile is   
 
 𝐼(𝑧) = 𝐼𝑜 ∗ 𝑒−∫ [𝜇+𝐶(𝑧)𝜀]𝑧𝑧0  𝑑𝑧 Equation 9 
 
 
where I is the intensity, Io is the incident intensity, µ is the tissue’s absorptivity, and ε is 
the drug’s molar absorptivity.  
For a given drug concentration profile and the corresponding light intensity profile, the 
instantaneous local cross-linking rate is quantified by the rate of change in modulus, 
dG'/dt obtained from collagen gel photorheology. The total change in local modulus after 
a given irradiation time, tirr is determined by summing over each instantaneous rate of 
increase in modulus.      
 
 
∆𝐺 ′(𝑧, 𝑡) = �  𝑑𝐺′
𝑑𝑡
�
𝑡,𝑧
𝑡𝑖𝑟𝑟
0
𝑑𝑡   Equation 10 
 
 
The average change in modulus of a sample, ∆G'avg, is determined by 
 
 
∆ 𝐺′𝑎𝑣𝑔 = 1𝐿� ∆𝐺 ′(𝑧)𝐿0 𝑑𝑧   Equation 11 
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to compare the extent of cross-linking for different treatment conditions.  
5.3 RESULTS 
Kinetics data – The rate of change in oscillatory storage modulus, dG'/dt, increased with 
increasing riboflavin concentration. Increasing the intensity at a given riboflavin 
concentration increased dG'/dt (Figure 5.2). The rate of change in modulus also increases 
with increasing eosin Y concentration. Increasing the intensity at a given eosin Y 
concentration increased dG'/dt. The highest riboflavin and eosin Y concentrations 
examined were limited by the minimum sample thickness that could be prepared and 
loaded onto the rheometer. Extrapolations using logarithmic fits provide estimated dG'/dt 
for concentrations above 0.05% riboflavin and 0.02% eosin Y. 
 
  a)          
       
  b) 
       
Figure 5.2. Rate of change in oscillatory storage modulus as a function of concentration 
for collagen gel samples with approximately uniform intensity profiles for a) riboflavin 
and b) eosin Y. (N = 4 to 12)  
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Model of riboflavin/UVA treatment – The riboflavin/UVA treatment currently going 
through clinical trials in the United States uses the procedure where riboflavin drops 
(0.1% riboflavin, 20% dextran) are applied every 2 minutes for 30 minutes followed UV 
irradiation (370 nm, 3 mW/cm2) for 30 minutes while adding riboflavin drops every 5 
minutes. For the clinical protocol treatment, the concentration profile is approximated for 
a drug contact time of 30 minutes (Figure 5.3a) which yields the corresponding intensity 
profile (Figure 5.3b) and cross-linking profile (∆G'avg is 503 Pa, Figure 5.3c).  
 
  a)   
  
  b)
 
 c) 
 
Figure 5.3. a) Concentration profile for 0.1% riboflavin with 30 minutes contact time.  
b) Light intensity profile for 3 mW/cm2 irradiation. c) Profile of modulus increase for 30 
minutes irradiation with ∆G'avg increased by 503 Pa.  
 
Model of eosin Y/visible light treatment – Drug concentration, contact time, and delay 
time determine the quantity and distribution of drug inside the tissue. For a given drug 
concentration profile, irradiation intensity and duration determine the extent of cross-
linking inside the tissue. The effect each individual treatment parameter has on the cross-
linking profile was examined (Table 5.1).  
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Table 5.1. Treatment parameters, their corresponding symbols, 
and figures showing their effects.  
Treatment parameters Symbols Results 
Drug concentration [Eosin Y] Figure 5.4 
Drug contact time tc Figure 5.5 
Delay time td Figure 5.6 
Irradiation intensity Io Figure 5.7 
Irradiation duration tirr Figure 5.8 
 
Effect of drug concentration – For a given contact time, increasing the drug concentration 
proportionately increases the concentration inside the tissue (Figure 5.4a). In turn, 
increasing the concentration causes the light intensity to decay more steeply (Figure 
5.4b).  
Increasing the concentration from 0.003% to 0.01% eosin Y, increases the extent of 
cross-linking everywhere in the tissue (average change in modulus, (∆G'avg, increases 
from 80 Pa to 104 Pa, Figure 5.4c); however, further increasing the concentration from 
0.01% to 0.03% decreases the light penetration depth from 146 μm to 38 μm (depth at 
which the intensity is 1/e of the incident intensity), resulting in most of the tissue with 
very little light for activating the reaction in the posterior side of the tissue (∆G'avg 
decreased from 104 Pa to 55 Pa). At 0.03% concentration, 75% of the cross-links form in 
the anterior 135 μm, compared to 290 μm for 0.01% concentration. 
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 a) 
 
  b) 
 
  c) 
 
Figure 5.4. a) Eosin Y concentration profile inside the tissue for three different drug 
concentrations after 5 minutes contact time. b) Corresponding light intensity profiles for 
the three different drug concentrations. c) Profile of modulus increase for each drug 
concentration after 5 minutes irradiation at 6 mW/cm2. The ∆G'avg in the tissue is 80 Pa 
for 0.003%, 104 Pa for 0.01%, and 55 Pa for 0.03%. 
 
Effect of drug contact time – For a given drug concentration, increasing the contact time 
increases the concentration everywhere in the tissue (provided the contact time is less 
than the characteristic time, which is the time it takes for drug molecules to penetrate the 
entire cornea, is given by L2/(4*D) ~ 15 minutes for eosin Y in the cornea). The increase 
in the amount of drug in the tissue (Figure 5.5a) causes the light intensity to decay more 
steeply with longer contact time (Figure 5.5b). Nevertheless, for 0.01% eosin Y, light 
penetrates the entire thickness even if the drug formulation is given 10 minutes contact 
time. Consequently increasing the contact time from 1 to 5 minutes, increases the extent 
of cross-linking everywhere in the tissue (∆G'avg increases from 76 to 104 Pa). Increasing 
the contact time from 5 to 10 minutes, results in a similar cross-linking profile (Figure 
5.5c). 
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 a) 
 
 b) 
 
 c) 
 
Figure 5.5. a) Eosin Y concentration profile inside the tissue for three different drug 
contact times using 0.01% eosin Y concentration. b) Corresponding intensity profiles for 
the three different drug contact times. c) Profile of modulus increase for each drug 
concentration after 5 minutes irradiation at 6 mW/cm2. The ∆G'avg in the tissue is 76 Pa 
for 1 minute, 104 Pa for 5 minutes, and 107 Pa for 10 minutes contact time. 
 
Effect of delay time – For a short contact time (less than the characteristic diffusion time), 
increasing the delay time between removal of the drug formulation and the inception of 
irradiation results in a more uniform concentration profile (Figure 5.6a). For 5 minutes 
contact time using 0.01% eosin Y, increasing the delay time, allows the high 
concentration near the anterior surface to decrease. In turn, this allows light to penetrate 
more deeply (Figure 5.6b), producing a more uniform distribution of cross-links after 5 
minutes of irradiation at 6 mW/cm2 (Figure 5.6c). While increasing the contact time from 
0 to 1 to 5 to 10 minutes yields increasingly uniform cross-linking profiles, it has little 
effect on ∆G'avg: 104 to 108 to 115 to 119 Pa, respectively.  
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  a) 
  
 b) 
  
 c) 
  
Figure 5.6. a) Eosin Y concentration profile inside the tissue for four different drug delay 
times using 0.01% eosin Y concentration with 5 minutes contact time. b) Corresponding 
intensity profiles for the four delay times. c) Profile of modulus increase for each drug 
concentration after 5 minutes irradiation at 6 mW/cm2. The ∆G'avg in the tissue is 104 Pa 
for 0 minute, 108 Pa for 1 minute, 115 Pa for 5 minutes, and 119 Pa for 10 minutes delay 
time. 
 
Effect of irradiation intensity – For a given concentration profile (Figure 5.7a) and a 
selected light dose (1.8 J/cm2), the combination of lower intensity and longer irradiation 
duration results in a greater ∆G'avg. This example uses the concentration profile predicted 
for topical application of a 0.01% eosin Y solution for 5 minutes contact time, removing 
the eosin Y from the surface and allowing 1 minute delay time, the corresponding light 
intensity profiles for three different irradiation intensities (Figure 5.7b), and the resulting 
cross-linking profiles for a light dose of 1.8 J/cm2 (Figure 5.7c). The ∆G'avg is 198 Pa for 
15 minutes at 2 mW/cm2, 139 Pa for 7.5 minutes at 4 mW/cm2, and 108 Pa for 5 minutes 
at 6 mW/cm2. The shape of the cross-linking profiles is similar for all irradiation 
intensities.  
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  a) 
 
 b) 
 
 c) 
 
Figure 5.7. a) Concentration profile for 0.01% eosin Y concentration with 5 minutes 
contact time and 1 minute delay. b) Light intensity profiles for three different irradiation 
intensities. c)  Profile of modulus increase for the same light dose of 1.8 J/cm2 using three 
pairs of intensity and irradiation duration. The ∆G'avg is 198 Pa for 15 minutes at 2 
mW/cm2, 139 Pa for 7.5 minutes at 4 mW/cm2, and 108 Pa for 5 minutes at 6 mW/cm2. 
 
Effect of irradiation duration – For a given concentration profile (Figure 5.8a) and a 
selected irradiation intensity (6 mW/cm2), ∆G'avg increases proportionally with irradiation 
time. This example uses the concentration profile predicted for topical application of a 
0.01% eosin Y solution for 5 minutes contact time, removing the eosin Y from the 
surface and allowing 1 minute delay time, the corresponding light intensity profile for 6 
mW/cm2 incident on the cornea (Figure 5.8b), and the resulting cross-linking profiles for 
three irradiation durations (Figure 5.8c). The ∆G'avg is 108 Pa for 5 minutes, 223 Pa for 
10 minutes, and 697 Pa for 30 minutes. The shape of the cross-linking profiles is similar 
for all irradiation intensities. 
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a)  
  
 b)
 
 c) 
 
Figure 5.8. a) Concentration profile for 0.01% eosin Y concentration with 5 minutes 
contact time and 1 minute delay. b) Corresponding light intensity profile for 6 mW/cm2 
irradiation. c)  Profile of modulus increase for three irradiation durations. The ∆G'avg is 
108 Pa for 5 minutes, 223 Pa for 10 minutes, and 697 Pa for 30 minutes. 
 
5.4 DISCUSSION 
Comparing riboflavin/UVA model to experimental data – Combining transport 
parameters and collagen cross-linking rates, we were able to build a model depicting the 
collagen cross-linking profile as a function of the depth in the tissue. Various studies 
have examined the extent of cross-linking in the anterior and posterior corneal stroma 
resulting from the riboflavin/UVA treatment by comparing changes in the resistance to 
enzymatic degradation[2], thermomechanical[13], collagen fibril diameter[14], hydration[15], 
and biomechanical behavior[7].  
Enzymatic degradation studies suggested the anterior portion of the stroma was more 
resistant to degradation compared to the posterior portion since the degradation process 
started at the posterior and moved toward the anterior portion[2]. This result agrees with 
the model which predicts a monotonically decreasing cross-linking profile over a 500 µm 
thick cornea for the riboflavin/UVA treatment (Figure 5.4c).  
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In porcine corneas (800 μm), the anterior portion of treated samples showed significant 
increase in the maximal hydrothermal shrinkage temperature whereas the posterior 
portion exhibited a much smaller increase (70.3°C in control samples, 71.2°C in the 
posterior 400 μm, and 75.0°C in the anterior 400 μm)[13]. The model predicts a ∆G'avg of 
609 Pa in the anterior 400 µm compared to 72 Pa in the posterior 400 μm portion of the 
cornea. This is consistent with the observed behavior where there is a large increase in 
the shrinkage temperature in the anterior portion due to a greater extent of cross-linking 
compared to the posterior portion.  
Collagen fiber diameter in treated rabbit corneas (400 μm) were found to increase by 
12.2% (3.96 nm) in the anterior portion and by 4.6% (1.63 nm) in the posterior portion 
compared to untreated corneas[14]. The model predicts a ∆G'avg of 916 Pa in the anterior 
200 μm compared to 267 Pa in the posterior 200 μm. The change in collagen fiber 
diameter in the anterior cornea is much greater than that of the posterior cornea which is 
consistent with the modeling results.  
Hydration studies in porcine corneas deduced an intensely cross-linked zone of 242 µm at 
the anterior surface, an intermediate cross-linked zone of 109 μm, and a non-cross-linked 
posterior zone of 501 μm[15]. The model predicts a ∆G'avg of 833 Pa in the anterior 242 
μm, 307 Pa in the next 109 μm, and 77 Pa in the 501 µm posterior portion.  
In human corneas (500 µm), the anterior portion of treated samples showed greater 
increase in the biomechanical strength compared the posterior portion[7]. The anterior flap 
increased by 254 x 103 N/m2 whereas the posterior flap increased by 36 x 103 N/m2 
relative to their corresponding controls. The model predicts a ∆G'avg of 916 Pa in the 
V-20 
 
anterior 200 μm compared to 267 Pa in the posterior 200 μm. Comparison of the results 
from previous experimental observations with those from the model show very close 
agreement which suggests the model is a good predictor of the cross-linking profile 
resulting from the treatment.  
Using the model, the predicted riboflavin concentration to maximize cross-linking with 
the clinical irradiation protocol (3 mW/cm2 for 30 minutes) is 0.044%, which yields a 
∆G'avg of 618 Pa whereas the clinical concentration (0.1%) only yields a ∆G'avg of 503 Pa 
(Figure 5.9). The clinical concentration yields a cross-linking rate that is only 81% of the 
optimal rate (collagen gel photorheology estimated 78% of the optimal rate, Chapter 3). 
In addition to providing a greater ∆G'avg, the optimal condition also produces a more 
uniform cross-linking profile. This is expected to be more advantageous since cross-links 
serve two purposes when halting the progression of keratoconus: to enhance 
biomechanical properties and to increase resistance to enzymatic degradation[2, 7, 8]. For 
an equivalent increase in tissue strength, a more uniform distribution of cross-links is 
expected to resist enzymatic degradation throughout the cornea better than a less uniform 
distribution.  
Even though an optimal treatment condition exists, it cannot be used due to the cytoxicity 
nature of riboflavin combined with UVA. The treatment requires a 0.1% riboflavin 
concentration to prevent a toxic UVA light dose from reaching the endothelium[17]. 
Because the combination of riboflavin and UVA light is cytotoxic, the clinical protocol 
was optimized for safety rather than efficacy[9]. Given available data on the combination 
of drug doses and irradiation intensities that are toxic, the model can also be used to 
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predict depth of keratocytes apoptosis and endothelial toxicity for various combinations 
of treatment parameters.  
 
  a) 
 
b) 
 
c) 
 
Figure 5.9. a) Riboflavin concentration profile after 30 minutes of topical drug 
application for clinical dose (0.1%) and optimal dose (0.044%). b) Light intensity 
profiles for 3 mW/cm2 irradiance. c)  Profile of modulus increase after 30 minutes of 
irradiation (∆G'avg is 503 Pa for clinical dose and 618 Pa for optimal dose). 
 
Selecting parameters for eosin Y/visible light treatment – Unlike riboflavin/UVA 
treatment, eosin Y/visible light is much more biocompatible (Chapter 6). Therefore the 
treatment parameters can be selected based on performance for efficacy instead of safety 
constraints. The model can be used to examine the role of each treatment parameter and 
its effect on the overall treatment. In turn, this knowledge can guide selection of 
treatment conditions that are desirable for clinical use.  
Selecting drug delivery protocol – The amount of drug transferred from the formulation 
into the cornea is determined by the drug concentration in the formulation and the contact 
time (time between topical application and removal of the formulation). The contact time, 
delay time, and irradiation duration determine how the drug is distributed inside the tissue 
at any given moment. Results from the model show that low eosin Y concentration ( ≤ 
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0.003% applied for 5 minutes, Figure 5.4a) inside the tissue provides a low cross-linking 
rate yielding a relatively small ∆G'avg for a given irradiation dose (Figure 5.4c). A high 
eosin Y concentration ( ≥ 0.03% applied for 5 minutes, Figure 5.4a) extinguishes most of 
the light in the anterior portion of the tissue (Figure 5.4b) leaving the posterior section 
untreated, resulting in a very non-uniform treatment (Figure 5.4c) and a lower ∆G'avg both 
of which are not favorable. Therefore, it is desirable to deliver a quantity of drug to the 
tissue that yields a fast reaction rate and a more uniform light intensity profile, producing 
a more uniform cross-linking profile. This desirable quantity is the amount such that the 
average concentration yields a light penetration depth similar to the tissue thickness. The 
optimal average drug concentration inside the tissue is 0.016%, and concentrations within 
the 0.016 ± 0.008% have cross-linking rates that are within 90% of the optimal 
concentration.  
Various combinations of eosin Y concentration and contact time can be selected to 
achieve the optimal quantity of drug inside the tissue: 0.027% with 1 minute contact time, 
0.012% for 5 minutes, or 0.0088% for 10 minutes. It is desirable for the treatment to have 
a short total treatment time and be reproducible. A longer treatment duration increases the 
risk of infection, increases patients’ discomfort, and requires more of a surgeon’s time 
which results in a higher cost. Applying a high drug concentration for a short contact time 
might have the disadvantage of high variability if the delivery time is not carefully 
monitored (Table 5.2). Increasing the contact time from 1 to 5 to 10 minutes decreases 
the variability in the quantity of drug delivered from 29% to 5% to 2%. A 5 minute drug 
contact time is recommended since it provides a relatively short contact time and low 
variability.   
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Table 5.2. Variability in drug quantity 
resulting from error in drug contact times 
by 30 seconds.  
tc (min) tc error (sec) Error (%) 
1  
- 30 - 29% 
+ 30 + 22% 
5  
- 30 - 5% 
+ 30 + 4% 
10  
- 30 - 2% 
+ 30 + 2% 
 
 
Once the desired amount of drug is delivered, adding a delay time before irradiating 
produces a more uniform concentration profile provided the contact time is less than the 
characteristic time (15 minutes, Figure 5.6a). A more uniform drug concentration profile 
provides a more uniform cross-linking profile (Figure 5.6c). Given the characteristic time 
is ~15 minutes, a 10 minutes total of combined contact time and delay time is sufficient 
to produce a relatively uniform distribution of drug inside the tissue (Figure 5.6a). For a 5 
minute contact time and 5 minute irradiation protocol, adding a delay time did not 
significantly alter the ∆G'avg or the cross-linking distribution (Figure 5.6c). For longer 
irradiation durations, the delay time effect becomes even less significant since the 
concentration profile continues to evolve during the irradiation period.  
Selecting irradiation protocol – Given a drug concentration profile, the irradiation 
intensity and duration determine the quantity of cross-linking but not the cross-linking 
distribution. Depending on how much cross-linking is necessary to halt the progression of 
keratoconus, the irradiation intensity and duration can be selected accordingly. In 
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selecting irradiation intensity and duration, factors that need to be considered are the 
safety limit of light permissible in the eye, maximum intensity level tolerable for patient 
comfort, and overall treatment duration. The light intensities and doses considered for 
corneal irradiation here are much lower than present in other applications such as 
bonding corneal incisions[18, 19], laser iridectomy and iridoplasty[20]. The light source (514 
nm at 640 mW/cm2 for 5 minutes or 192 J/cm2) used in bonding corneal incision over a 
1-cm diameter area did not result in tissue damage to the animals monitored over a 10-
week period[18]. This amount of light is 2 orders of magnitude more than the light dose 
used in the examples above for a 5 minute irradiation period at 6 mW/cm2. 
(Biocompatibility studies in Chapter 6 show a 3.6 J/cm2 light dose combined with eosin 
Y is well tolerated by the cornea with no toxicity to the endothelium and very little 
damage to keratocytes compared to riboflavin/UVA treatment.)     
Results show that for the same light dose, selecting a lower irradiation intensity with a 
longer duration results in more cross-linking than a higher intensity with a shorter 
duration. However, since the maximum exposure limit is very high, a higher intensity (6 
mW/cm2) and shorter irradiation period can be selected to minimize the overall treatment 
duration. The other factor to consider in selecting the intensity is the level of discomfort 
patients can tolerate.     
5.5 CONCLUSION 
The photo-activated collagen cross-linking treatment has multiple parameters that are 
interdependent and with a model we are able to predict the cross-linking profile resulting 
from adjusting individual or combinations of different parameters. The parameter space is 
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very large and carrying out experiments to find optimal values would be daunting. This is 
a powerful tool that can help narrow down the parameter space for selecting optimal 
values to be used in the clinic.  
This model can be used to create customized treatments for individual patients depending 
on how severely the disease has progressed and how much cross-linking is necessary to 
treat the patient. Once the amount of cross-linking necessary to halt the progression of the 
disease in each patient is better understood, this model can also help customize treatments 
for individual patients so that they are effective, safe and as comfortable for the patients 
as possible.    
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Chapter 6 
Cross-linking the Cornea with Minimal Toxicity 
 
6.1 INTRODUCTION 
Keratoconus is a bilateral corneal disorder with a prevalence of 1 out of 2,000 without 
racial or gender bias[1, 2]. This eye disease is characterized by progressive corneal 
thinning, protrusion, and scarring, resulting in irregular astigmatism and myopia. Corneal 
thinning appears to result from loss of material, partly due to the increased collagen 
degradation rate[3, 4]. The cornea of keratoconic eyes are found to have fewer collagen 
lamellae, fewer collagen fibrils per lamella, closer packing of collagen fibrils or various 
combinations of these factors resulting in a weakened structure[1].  
Corneal thinning results in visual impairment that can be corrected by spectacles in the 
early stages of the disease. As corneal irregularities increase, eyeglasses are not sufficient 
to provide clear vision, so contact lenses are used. Patients who do not tolerate contact 
lenses, may undergo surgical procedures, such as thermokeratoplasty[5], 
epikertaophakia[6], and intracorneal ring segments[7] to reduce refractive errors induced 
by irregular corneal thinning associated with the disease; however, these treatments do 
not halt the progression of the keratoconus. When the disease progresses to the stage 
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where contact lenses no longer suffice, a corneal transplant (keratoplasty) is required. 
About 20% of patients with keratoconus ultimately require keratoplasty[1]. 
Pioneering research of Wollensak, Seiler, and Spoerl demonstrated that photodynamic 
corneal collagen cross-linking using riboflavin and UVA could halt the progression of 
keratoconus[8-10]. Five major human clinical trials in different countries ranging from 3 
months to 6 years have demonstrated riboflavin/UVA treatment is effective in treating 
keratoconus[11]. The current protocol requires topical application of drug solution (0.1% 
riboflavin with 20% dextran) to the cornea every 2 minutes for 30 minutes before 
irradiating, and every 5 minutes during 30 minutes of irradiation with 3mW/cm2 UVA 
light.  
The combination of riboflavin and UVA is toxic to both keratocytes and endothelial cells. 
Since endothelial cells cannot regenerate in human eyes, the treatment was carefully 
designed to restrict toxicity to the anterior 350 μm of the corneal stroma[12]. This is 
achieved by selecting a high drug concentration and applying it for an extended duration 
to limit the amount of UVA light reaching the endothelium. The treatment cannot be used 
on patients with corneas under 400 μm since it causes “significant necrosis and apoptosis 
of endothelial cells” in rabbit corneas[13]. Keratocyte apoptosis causes corneal haze until 
they completely regenerate after 6 months, and in some cases, it takes up to 12 months to 
recover completely[3, 14, 15]. Even though there is toxicity, patients are willing to risk 
damaging their eyes to receive this treatment (currently being used in Europe and is going 
through FDA clinical trials in the U.S.) over the alternative treatment (corneal transplant). 
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Because riboflavin/UVA treatment has many safety concerns, it has been suggested that 
selecting a photosensitizer in the visible spectrum might reduce harmful effects[11]. Eosin 
Y is a photosensitizer with an absorption peak in the visible range (514 nm) which has 
shown the ability to cross-link collagen[16, 17] and stabilize sclera tissue[18]. It has also 
been approved for use in the body by the FDA[19].    
6.2 METHODS 
In Vitro Treatment – Eyes from New Zealand White Rabbit ranging from 2 to 3 kg were 
provided by collaborator Dr. Keith Duncan at the University of California at San 
Francisco. Eyes were shipped and stored in balanced saline on ice until use within 48 
hours of enucleation. The epithelial cell layer was removed by scraping with a scalpel 
until epithelial material could be seen on the scalpel and the surface of the cornea 
changed from a smooth texture to a matte texture. The eyes were then placed into 
Dulbecco’s phosphate buffer saline (DPBS) until treatment (within 30 minutes). Orbital 
tissues (muscle, fat, conjunctiva) covering the sclera and corneoscleral limbus were left in 
place for treatment to simulate the in vivo condition with respect to drug reaching the 
sclera. 
Eosin Y/visible light treatment (EY/vis) – Eosin Y gel (0.04% w/w eosin Y and 3% w/w 
carboxymethylcellulose in DPBS) was prepared and then transferred into a 10 mL 
syringe. Using the syringe, ~0.5 mL of gel was applied onto the cornea. After 5 minutes 
contact time, the gel was removed from the corneal surface by squirting DPBS onto the 
cornea. The eye was then placed onto a holder with the cornea facing up to receive 
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irradiation from an array of green light emitting diodes (seven 5-mm LEDs at 525 ± 16 
nm, 6 mW/cm2 in the plane of the cornea). Irradiation was applied for 10 minutes. 
The concentration and contact time were selected based on the results in Chapter 5 
showing a cornea immersed in 0.016 ± 0.008% eosin Y solution for 5 minutes delivers 
the optimal amount of drug. To err on the side of having more drug in the cornea, a 
concentration of 0.02% was selected. In order to deliver an equivalent amount of drug in 
a gel form, twice the concentration is necessary in a gel formulation (0.04% eosin Y, 3% 
carboxymethylcellulose in DPBS) based on measurements using the light absorption 
technique discussed in Chapter 2. Results from the model in Chapter 5 show that adding a 
delay time before irradiation does not significantly affect the cross-linking profile. 
Therefore, the corneas in these experiments were irradiated immediately after removal of 
the drug formulation from the corneal surface.  
Riboflavin/UVA treatment (R/UVA) – Following the R/UVA protocol used in clinical 
trials in the United States, the eye was placed onto a holder with the cornea facing up to 
receive drops of riboflavin (0.1% w/w riboflavin-5’-monophosphate and 20% w/w T-500 
dextran in DPBS) and irradiation. Riboflavin drops were applied onto the cornea every 2 
minutes for 30 minutes. The eye was then irradiated using a similar light set up described 
above but with UV LEDs (370 ± 12 nm, 3 mW/cm2). Irradiation was applied for 30 
minutes while adding riboflavin drops every 5 minutes.  
Control treatment – Nothing was done to the eye other than removal of the epithelium.  
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After treatment, all eyes were placed into DPBS (Table 6.1). Orbital tissues were 
removed with scissors to expose the sclera and ensure accurate analysis of the eye shape.  
                
Table 6.1. In vitro treatment summary 
Treatment Drug  Light (min) # of Eyes 
EY/vis Eosin Y gel, 5 min 10 8 
R/UVA Riboflavin drops, 30 min 30 8 
Control None None 12 
 
Intact Globe Expansion – Intact globe expansion was performed following the procedure 
described by Mattson, et al.[20]. Eyes were mounted onto acrylic cylinders inside of a 
transparent plexi-glass observation cell filled with DPBS (Figure 6.1). To minimize 
bacteria growth during the experiment, several drops of antibiotic eye drops (Bausch & 
Lomb neomycin, polymyxin B sulfate and gramicidin ophthalmic solution USP) were 
added to the DPBS solution in the observation cell. The eyes were aligned with the major 
axis of the equator parallel to the imaging plane. There are two holes sealed with rubber 
septa used for inserting 30 gauge hypodermic needles to control the intraocular pressure 
(IOP). The needles were inserted into the eyes through the posterior sclera. The needles 
were connected to a DPBS reservoir set at a height h above the eyes to impose a desired 
IOP governed by hydrostatic pressure (IOP = ρgh; ρ = density, g = gravitational 
acceleration). To minimize activation of any residual photosensitizer present in the tissue, 
the experiment was performed in the dark except for 15 seconds of illumination from a 
fluorescent lamp every15 minutes to provide light for the photographs. For the first hour, 
the IOP was held at 15 mmHg to restore the shape of the eye (since shipping and 
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handling results in a variable shape). Then IOP was switched to 300 mmHg until the 
experiment completed (when rupture was observed or the level of fluid in the reservoir 
began to drop due to leaks in the tissue). 
Photographs of the eyes were taken every 15 minutes throughout the experiment then 
analyzed for changes in ocular dimensions (corneal perimeter – CP, corneal length – CL, 
and corneal diameter – CD) using a custom MATLAB program. The rate of change for 
each of the three corneal dimensions was characterized using the difference between their 
initial value (using the image acquired 15 min after the pressure was changed from 15 to 
300 mmHg) and their final value (described below) divided by the elapsed time between 
the initial and final images. The initial image is selected to be 15 minutes after switching 
on high pressure to avoid the variability in the transient response during the first few 
minutes after the large IOP change. For example, the rate of change of the corneal 
perimeter, d(∆CP)/dt, is calculated using 
 
 𝑑(∆𝐶𝑃)
𝑑𝑡
=  𝐶𝑃𝑓 − 𝐶𝑃𝑖
𝐶𝑃𝑖
× 1
𝑡𝑐
 Equation 1 
 
 
 
where CPi is the initial corneal perimeter, CPf is the corneal perimeter measured at end of 
the creep period. The end of the creep period is selected to be 2 hours before the first eye 
undergo tissue failure occurred so that calculated rates are due to creep and not tissue 
defects leading to failure (20 hours for in vitro experiments and 30 hours for in vivo 
experiments). CL and CD were computed using the same equation replacing CP with the 
either CL or CD. 
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  a) 
 
 b) 
 
 
 c) 
 
  
     CP: Corneal Perimeter 
     CL: Cornea Length 
     CD: Corneal Diameter 
Figure 6.1. a) Intact globe expansion apparatus. Ocular dimensions b) are recorded with 
photographs and c) measured with custom MATLAB software. 
 
 
In Vivo Treatment – New Zealand White Rabbits ranging from 2 to 3 kg were treated at 
UCSF in collaboration with Dr. Keith Duncan. Each rabbit was given general anesthesia 
with 1-5% inhaled isofluorane administered by mask. A speculum was inserted into the 
rabbit eyelid to keep the eye open for treatment. Drops of 0.5% proparacaine were 
applied onto the eye followed by sterilization with 5% povidone-iodine (betadyne). The 
eye was then rinsed with ocular balanced saline solution (BSS). The epithelium was 
removed by dipping a Weckcell sponge into 40% ethanol solution then rubbing it against 
the corneal surface until the epithelium came off.  
Eosin Y/visible light treatment – Approximately 0.5 mL (between 0.4 to 0.6 mL) eosin Y 
gel was applied to the cornea using a syringe. After 5 minutes contact time, the gel was 
removed by rinsing the cornea with BSS. Within 1 minute, the cornea was irradiated with 
with 525 ± 16 nm light at 6 mW/cm2 for 10 minutes. The fellow eye served as a control: 
BSS drops were applied to the cornea for 1 minute then followed by 10 minutes of 
irradiation as above.  
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Riboflavin/UVA treatment – Riboflavin drops were applied onto the cornea every 2 
minutes for 30 minutes. The eye was then irradiated with 370 ± 12 nm light at 3 
mW/cm2. Irradiation was applied for 30 minutes while adding riboflavin drops every 5 
minutes. The fellow eye served as a control, receiving BSS drops for 1 minute followed 
by 30 minutes UV irradiation while adding BSS drops every 5 minutes. 
              
Table 6.2. In vivo treatment summary for efficacy study 
Treatment Drug  Light (min) # of Eyes 
EY/vis Treated Eosin Y gel, 5 min 10 8 
EY/vis Control BSS, 1 min 10 8 
R/UVA Treated Riboflavin drops, 30 min 30 4 
R/UVA Control BSS, 1 min 30 3* 
*One R/UVA Control eye was damaged during enucleation. 
 
After irradiation, the eye was rinsed with BSS followed by application of antibiotic eye 
drops. The treatment was completed and the speculum was removed (Table 6.2). Animals 
were sacrificed 24 hours after treatment. The eyes were enucleated, stored in BSS on ice, 
and shipped to Caltech overnight. All eyes were tested within 12 hours of arrival (within 
36 hours of enucleation) using the intact globe expansion apparatus described above. 
Biocompatibility – Treatments were performed in vivo at UCSF in collaboration with Dr. 
Keith Duncan according to the procedures described above. After treatment, eyes were 
observed for inflammation, corneal haze, and epithelial regrowth over a period of 7 days. 
Another set of in vivo studies was performed for histology. The treatments used the same 
in vivo procedure described above. Animals were sacrificed 24 hours after treatment. 
VI-9 
 
Eyes were enucleated and fixed in 10% formalin, embedded in paraffin, and sections 
were cut and stained with eosin and hematoxylin.   
                     
Table 6.3. In vivo treatment summary for biocompatibility study 
Animal  Eye Drug  Light (min) 
1 
OD Eosin Y gel, 5 min 0 
OS None 0 
2 
OD Eosin Y gel, 5 min 10 
OS None 10 
3 
OD Riboflavin drops, 30 min 30 
OS BSS, 1 min 30 
 
6.3 RESULTS 
Results for in vitro treated eyes showed that treated eyes resisted expansion relative 
controls as measured by all three corneal dimensions (Table 6.4, * indicates p < 0.05). 
The rate of change of CP, d(∆CP)/dt, is most closely related to the (approximately 
biaxial) strain rate during exposure to IOP = 300 mmHg. Due to the strength of the sclera, 
the corneal diameter generally expands less than the corneal perimeter (i.e., d(∆CD)/dt < 
d(∆CP)/dt) and, consequently, CL increases more than CP (i.e., d(∆CL)/dt > d(∆CP)/dt).  
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Table 6.4. 104 * Rate of change in corneal dimensions. (CP = corneal 
perimeter, CL = corneal length, CD = corneal diameter) 
   d(∆CP)/dt  d(∆CL)/dt  d(∆CD)/dt 
In
 v
itr
o Control (N = 12)  23 ± 7  59 ± 19  16 ± 8 
EY/vis (N = 8)  *3 ± 5  *2 ± 9  *5 ± 4 
R/UVA (N = 8)  *13 ± 10  *15 ± 18  *13 ± 7 
In
 v
iv
o Control (N = 11)  12 ± 6  18 ± 11  10 ± 4 
EY/vis (N = 8)  *6 ± 5  10 ± 8  *5 ± 5 
R/UVA (N = 4)  *2 ± 3  8 ± 3  *0 ± 3 
*Indicates statistically significant difference (p < 0.05) from control group 
for each treatment type (in vitro and in vivo). 
 
In
 v
itr
o 
  a)                         
 
b) 
  
c) 
   
In
 v
iv
o 
   
Figure 6.2. Rate of change in a) corneal perimeter (CP) b) corneal length (CL) and  
c) corneal diameter (CD) for different treatment groups. The asterisk indicates a 
statistically significant difference compared to the control group (p < 0.05). (For in vitro 
experiments, Control: N = 12; EY/vis: N = 8; R/UVA: N = 8. For in vivo experiments, 
Control = 11; EY/vis: N = 8; R/UVA: N = 4)    
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By any of these measures, the deformation of the treated corneas is 1/2 or less that 
observed for controls (Figure 6.2). The EY/vis treatment is comparable to the 
riboflavin/UVA treatment; there is no statistically significant difference between these 
two groups. 
Results for in vivo treated eyes show fellow controls respond identically in the EY/vis 
and R/UVA groups: respectively, the rates of increase of CP were 0.19 ± 0.12 %/hr and 
0.14 ± 0.07 %/hr; of CL were 0.27 ± 0.20 %/hr and 0.28 ± 0.09 %/hr; and of CD were 
0.15 ± 0.08 %/hr and 0.08 ± 0.06 %/hr. Therefore, the results for the controls are treated 
in aggregate. Control eyes from the in vivo study resist deformation relative to controls in 
the in vitro study (cf., top row to bottom row of Figure 6.2). The exact origin of this 
difference is not yet known. 
Results for in vivo treated eyes showed that treated eyes resisted expansion relative to 
controls (Table 6.1, * indicates p < 0.05). The creep rates of the in vivo treated groups are 
less than or approximately ½ those of the controls for all three corneal dimensions 
(Figure 6.2). The EY/vis treatment is comparable to the riboflavin/UVA treatment; there 
is no statistically significant difference between these two groups. 
Two types of biocompatibility studies compare riboflavin/UVA and eosin Y/vis: 
examination of corneal recovery during the first week after treatment; and histological 
examination of acute toxicity during the first 24 hours. In the first, animals were 
examined on Day 2 and Day 7 after treatment, recording observations of inflammation, 
corneal haze, and epithelial regrowth (Table 6.5). The EY/vis treatment was 
indistinguishable from balanced salt solution (BSS) control in all animals by all 
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measures, with the exception of a delay in re-epithelialization in one animal. R/UVA 
treated eyes showed moderate inflammation and severe corneal haze on Day 2, which 
was absent in BSS controls and EY/vis treated eyes. The inflammation resolved and the 
corneal haze became mild after 7 days. Epithelial regrowth only occurred in patchy areas 
covering approximately 1/3 of the debrided area after 7 days, in stark contrast to BSS 
controls or EY/vis treated eyes.             
Table 6.5. Eosin Y/ visible light treatment biocompatibility 
  Day 2 Day 7 
Animal Eye Inflam-
mation 
Corneal 
Haze 
Inflam-
mation 
Cornea
l Haze 
Epithelial 
Regrowth 
1 
EY/vis None None None None 100% 
BSS/vis None None None None 100% 
2 
EY/vis None None None None 100% 
BSS/vis None None None None 100% 
3 
EY/vis None None None None ~50% 
BSS/vis None None None None 100% 
4 
EY/vis Mild Mild None None ~50% 
BSS/vis Mild Mild None None ~50% 
 
              
 
Table 6.6. Riboflavin/UVA treatment biocompatibility 
  Day 2 Day 7 
Animal Eye Inflam-
mation 
Corneal 
Haze 
Inflam-
mation 
Cornea
l Haze 
Epithelial 
Regrowth 
1 
R/UVA Moderate Severe None Mild ~33% 
BSS/UVA Mild Mild None None 100% 
2 
R/UVA Moderate Severe None Mild ~33% 
BSS/UVA Mild Mild None None 100% 
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Histology performed on corneal cross-sections of animals sacrificed 24 hours after 
treatment shows that BSS controls are insensitive to irradiation with either visible or 
UVA light (second row, Figure 6.3). Apoptosis of keratocytes and the presence of some 
inflammatory cells are observed in the anterior 1/3 of the stroma in all of the BSS 
controls, in accord with that associated with the response to de-epithelialization[21]. The 
posterior half of the stroma and the endothelium in all three BSS controls show the usual 
number and morphology of keratocytes, as well as an intact endothelium. Apoptosis of 
keratocytes and the presence of some inflammatory cells in the anterior 1/3 of the stroma 
are also evident in the corneas that received EY (no light) and EY/vis (top, Figure 6.3a-
b). The number and morphology of keratocytes in the posterior half of the stroma and the 
intact endothelium observed in both EY (no light) and EY/vis are similar to the BSS 
controls (compare top to bottom, Figure 6.3a-b). The corneas treated with EY (no light) 
and EY/vis are indistinguishable, indicating that phototoxicity is negligible in the case of 
EY/vis. The R/UVA treated eye was completely devoid of keratocytes in the stroma and 
no endothelial cells remained (Figure 6.4c top), in accord with prior literature on the 
phototoxicity of R/UVA[13]. The fellow eye treated with BSS/UVA has an intact 
endothelial cell layer, a normal distribution of keratocytes in most of the cornea with a 
few inflammatory cells in the anterior section of the stroma (Figure 6.4c bottom), in 
accord with prior studies that showed the phototoxicity of riboflavin is not elicited by the 
UVA irradiation alone[22]. 
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  a) EY/vis 
 
  
  b) EY/no light 
 
 
  c) R/UVA 
 
  
 
  BSS/Vis 
 
  
 
  BSS/no light 
 
 
 
  BSS/UVA 
 
  
 
Figure 6.3. Representative corneal cross-sections 24 hours after treatment. The left side 
of each image is the anterior side and the right side is the posterior side of the cornea. The 
epithelium is absent because it was removed in the treatment procedure. Cornea treated 
with a) eosin Y and 525 nm light (top), BSS and 525 nm light (bottom) b) eosin Y and no 
light (top), BSS and no light (bottom) and c) riboflavin and 370 nm light, BSS and 370 
nm light.  
 
 
6.4 DISCUSSION 
Eosin Y/vis treatment and R/UVA treatment produce similar stabilization of rabbit 
cornea as indicated by resistance to creep when challenged by elevated intra-ocular 
pressure. Similar efficacy is observed both when the treatment is applied in vitro and 
when treatment is performed in vivo in a rabbit model. The R/UVA treatment is found to 
be effective in studies lasting up to 6 years due to the stable nature of the cross-links 
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formed. Cross-links induced by EY/vis are expected to be equivalent to the ones formed 
by R/UVA (Chapter 2). So they should resist hydrolysis and enzymatic degradation in a 
similar manner. Therefore, it is worth investigating the expectation that EY/vis would 
also provide the long term efficacy. 
While the efficacy of the two treatments are comparable, the toxicity of R/UVA is much 
more severe than that of EY/vis as measured by the degree of inflammation, epithelial 
regrowth, corneal haze (Table 6.4 and 6.5), and cytotoxicity (Figure 6.3). In addition, the 
total treatment time for the R/UVA protocol (60 minutes) is four times longer than that 
for the EY/vis treatment (15 min) (Figure 6.2).  
Consistent with previous studies, corneal haze was observed after R/UVA  
treatment[3, 14, 15], which has been attributed to keratocytes apoptosis. Keratocyte 
apoptosis causes edema formation leading to stromal haze. In accordance, keratocyte 
apoptosis was observed throughout the rabbit corneas treated with R/UVA (Figure 6.3). 
Numerous studies have documented keratocyte apoptosis resulting from R/UVA 
treatment down to a depth of 300-350 µm, which leads to corneal haze in patients post-
operatively ranging from weeks to months until keratocytes repopulate the cornea[9, 23-25]. 
Typically, repopulation of keratocytes begins 2-3 months after treatment and reaches a 
normal density after 6 months[25, 26]. Corneal haze of various degrees in patients has been 
reported to last for up to 12 months before resolving completely[10]. In 7.6% of the cases, 
corneal haze becomes permanent[27] resulting in impaired vision.   
EY/vis treatment induced little or no corneal haze, which is consistent with histology 
results showing a normal distribution of keratocytes in most of the stroma (Table 6.4 and 
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Figure 6.3a). Keratocyte apoptosis in the anterior section of the cornea was also observed 
in the control groups due to removal of the corneal epithelium[21]. Based on these 
observations in a rabbit model, it is worth investigating the expectation that EY/vis would 
cause very mild keratocyte toxicity, little corneal haze and faster recovery in patients. If 
this were borne out in clinical studies, the implication would be that patients could 
receive corneal cross-linking without the inconvenience of months of corneal haze 
currently experienced by patients receiving R/UVA treatment.  
In addition to keratocyte toxicity, R/UVA treatment also induced endothelial cytotoxicity 
(Figure 6.3c, bottom), which has also been observed in previous studies[13, 28]. Endothelial 
cytotoxicity in rabbit corneas resulting from the treatment has been attributed to their thin 
corneas (400 μm or less). In such thin corneas, the light intensity reaching the 
endothelium is high enough to cause damage. Therefore, it has been established that the 
treatment cannot be performed on patients with corneas thinner than 400 μm[9, 12, 13]. 
EY/vis treatment was very well tolerated by the endothelial cell layer in rabbit corneas; 
treated eyes have indistinguishable endothelial cell layers compared to fellow control 
eyes (Figure 6.3a). Based on these observations in a rabbit model, it is worth 
investigating the expectation that EY/vis treatment would be safe for treatment of 
advanced keratoconus patients with corneas thinner than 400 μm. If this were borne out 
in clinical studies, the EY/vis treatment might also be safe for post-LASIK ectasia 
patients, who tend to have thin corneas due to removal of corneal tissue during 
LASIK[29]. 
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6.5 CONCLUSION 
Corneal collagen cross-linking by production of singlet oxygen upon irradiation of a 
photosensitizer occurs with both riboflavin (irradiated with UVA) and eosin Y (irradiated 
with green light). Cross-links formed by riboflavin are found to be stable in studies 
lasting up to 6 years and those formed by eosin Y are expected to be equivalent (Chapter 
2), so it should produce long-term stability as well. The two approaches are shown to 
confer similar stabilization of rabbit cornea. Stark differences between the two treatments 
are seen in corneal toxicity, with little phototoxicity observed for the EY/vis treatment. 
Of particular interest, no endothelial toxicity was observed with EY/vis in a rabbit model, 
even though the cornea is less than 400 µm thick. Therefore, future clinical studies are 
recommended to determine if EY/vis treatment is safe for patients with corneas thinner 
than 400 μm. Relative to the usual R/UVA clinical protocol, the EY/vis protocol requires 
1/4 the treatment time (15 minutes). If clinical studies confirm the results seen in a rabbit 
model, the EY/vis treatment might reduce patient discomfort and treatment cost relative 
to R/UVA. Clinical studies are highly recommended to further investigate safety and 
efficacy of EY/vis treatment, which has the ability to retain the benefits of corneal cross-
linking demonstrated by R/UVA while significantly reducing toxicity and treatment 
duration. 
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